Mirror selection of L-nucleic acid aptamers
Screening of L-DNA aptamers through mirror selection schemes and electrophoresis technology solves the problem of targeting target molecules such as large proteins in the prior art, improves the biological stability of the aptamers, and expands the application potential of mirror biology.
Patent Information
- Application Number
- CN202380032837.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-17
- Filing Date
- 2023-02-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-02-02
AI Technical Summary
It is difficult for the prior art to effectively select and synthesize mirror nucleic acid aptamers targeting biological important target molecules such as large proteins, resulting in limited application of mirror biological science, and mirror aptamers have poor stability in vivo, making it difficult to widely use in diagnosis and treatment.
Using a mirror selection scheme, L-DNA aptamers are directly selected through large randomized L-DNA libraries, and combined with denaturing gradient gel electrophoresis and phosphorothioate sequencing technology, the L targeting natural human thrombin is selected and amplified by iterative rounds. -DNA sequence, high-affinity L-DNA aptamers were screened out, and PCR amplification and sequencing were performed by D-amino acid polymerase.
Successfully expanded the application of mirror biological systems, improved the biostability of L-DNA aptamers, and enabled them to resist the degradation of nucleases and proteases in vivo. They are suitable for biosensors and therapeutic agents, and are suitable for low-purity target molecules. and cell tissue selection.
Smart Images

Figure SMS_1 
Figure SMS_3 
Figure SMS_4
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of priority to U.S. Application No. 63 / 306,139, filed on February 3, 2022, and U.S. Application No. 63 / 311,092, filed on February 17, 2022, which are incorporated herein by reference in their entireties.
[0003] Sequence Listing Statement
[0004] The file entitled 94498.xml containing 12,923,440 bytes created on February 1, 2023, filed concurrently with the filing of this application is incorporated herein by reference.
[0005] FIELD AND BACKGROUND OF THE INVENTION
[0006] The present invention, in some embodiments thereof, relates to methods of selecting L-nucleotide aptamers and methods of sequencing the same.
[0007] Aptamers are nucleic acid polymer ligands that bind to specific target molecules via tertiary interactions and are selected by systematic evolution of ligands by exponential enrichment (SELEX) or in vitro selection. Natural, unmodified aptamers are easily degraded by ubiquitous nucleases in vitro and in vivo, greatly limiting their practical application as diagnostic and therapeutic tools. Although chemical modification and xeno nucleic acid (XNA) design have been shown to enhance aptamer stability, their discovery and production require designed, specialized nucleotides, and even so, nuclease degradation of non-natural nucleic acid aptamers cannot be completely avoided.
[0008] Chirally inverted L-DNA or L-RNA aptamers (mirror aptamers) with excellent biostability both in vitro and in vivo have been selected to bind natural target molecules. Their large-scale production can be easily achieved by automated oligonucleotide synthesizers with commercially available L-deoxynucleosides or L-ribonucleoside phosphoramidites, making them ideal for practical applications in diagnosis and treatment. Since recognizing their biochemical advantages more than two decades ago, mirror aptamers have been selected mainly through an indirect scheme known as 'selection-reflection': first chemically synthesize a mirror version of the target molecule for selecting the D-aptamer, and then synthesize a mirror aptamer with the same sequence to bind the corresponding natural target. However, the first step of chemically synthesizing mirror target molecules is often problematic, particularly for proteins with large size, extensive post-translational modifications (PTMs) and low in vitro folding efficiency. In practice, based on current technology, most biologically important target molecules, such as large proteins, cannot be chemically synthesized and correctly folded. As a result, only a small number of mirror-image aptamers have been discovered through selection-reflection in more than two decades, all of which target small molecules, short peptides, short RNAs and small proteins, the largest of which is the 12 kDa 110-amino acid (aa) ribonuclease (barnase) from Bacillus amyloliquefaciens, while the selection of mirror-image aptamers targeting the vast majority of biologically important but unsynthetable target molecules has not yet been achieved.
[0009] Background technology includes U.S. Patent Application No. 20210332360, U.S. Patent No. 11,015,178, and U.S. Patent No. 10,975,370. SUMMARY OF THE INVENTION
[0011] According to one aspect of the present invention, there is provided a method for screening a plurality of L-nucleic acid aptamers for L-nucleic acid aptamers having binding affinity to a target molecule, comprising:
[0012] (a) contacting the plurality of L-nucleic acid aptamers with the target molecule under conditions in which the target-bound L-nucleic acid aptamers are selectively captured from the plurality of L-nucleic acid aptamers;
[0013] (b) amplifying the L-nucleic acid aptamer of the target-binding L-nucleic acid aptamer to generate an amplified double-stranded L-nucleic acid oligonucleotide; and
[0014] (c) The amplified double-stranded L-nucleic acid oligonucleotides are separated using an electrophoresis-based method, thereby screening a variety of L-nucleic acid aptamers.
[0015] According to another aspect of the present invention, a kit for identifying an L-nucleic acid aptamer comprises:
[0016] (i) calf intestinal phosphatase (CIP);
[0017] (ii) L-deoxyribonucleotide triphosphate (L-dNTP) or modified L-dNTP; and / or
[0018] (iii) a polymerase capable of adding one or more L-nucleotides to the 3' end of the first L-nucleic acid.
[0019] According to another aspect of the present invention, there is provided a method for sequencing a purified L-DNA molecule, comprising:
[0020] (a) treating a sample comprising purified L-DNA molecules with a phosphatase under conditions that remove the 3'-monophosphate from the L-DNA molecules: and
[0021] (b) subjecting the sample to phosphorothioate sequencing, thereby sequencing the purified L-DNA molecules.
[0022] According to another aspect of the present invention, there is provided an isolated thrombin-binding L-DNA aptamer comprising a sequence as shown in SEQ ID NO: 10, 12, 14, 16, 27 or 28 or a sequence having at least 80% identity thereto.
[0023] According to one embodiment of the present invention, the method further comprises converting the amplified double-stranded L-nucleic acid oligonucleotide into a single-stranded oligonucleotide after step (b) and before step (c).
[0024] According to one embodiment of the present invention, steps (a) and (b) and the conversion step are repeated at least 3 times to enrich the target-binding L-aptamer before separation.
[0025] According to one embodiment of the present invention, the method further comprises monitoring the enrichment of the target-bound L-aptamer.
[0026] According to one embodiment of the present invention, said monitoring is achieved by electrophoretic mobility shift assay (EMSA).
[0027] According to one embodiment of the invention, the electrophoresis-based method is selected from the group consisting of native PAGE; denaturing PAGE; denaturing gradient gel electrophoresis (DGGE); constant denaturing gel electrophoresis (CDGE) and time temperature gradient gel electrophoresis (TTGE).
[0028] According to one embodiment of the present invention, the electrophoresis-based method comprises DGGE.
[0029] According to one embodiment of the present invention, the target molecule is selected from the group consisting of peptides, polypeptides, small molecules, carbohydrates and nucleic acid molecules.
[0030] According to one embodiment of the present invention, the target molecule is contained in a cell or a tissue.
[0031] According to one embodiment of the present invention, the amplification utilizes D-amino acid polymerase.
[0032] According to one embodiment of the present invention, the D-amino acid polymerase is selected from D-ASFV pol X, D-Taq polymerase, D-Pfu polymerase, Sulfolobus and solfataricus P2 DNA polymerase IV (DPO4), a fusion protein comprising the DPO4, and a polymerase having an amino acid sequence that is at least 80% identical to DPO4.
[0033] According to one embodiment of the present invention, the polymerase has an amino acid sequence as shown in SEQ ID NO:38 or SEQ ID NO:40.
[0034] According to one embodiment of the present invention, the method further comprises sequencing the separated members after step (c) to obtain the sequence of the L-aptamer having binding affinity to the target molecule.
[0035] According to one embodiment of the present invention, the sequencing is achieved using a method selected from the following: L-DNA chemical sequencing; L-DNA phosphorothioate sequencing; L-DNA dideoxy sequencing; L-DNA ion torrent sequencing; L-DNA Illumina sequencing; and L-DNA nanopore sequencing.
[0036] According to one embodiment of the present invention, the method is L-DNA phosphorothioate sequencing.
[0037] According to one embodiment of the present invention, the method further comprises contacting the amplified double-stranded L-nucleic acid oligonucleotide with a phosphatase prior to the sequencing.
[0038] According to one embodiment of the present invention, the phosphatase comprises calf intestinal phosphatase (CIP).
[0039] According to one embodiment of the present invention, each L-nucleic acid aptamer in the plurality of L-nucleic acid aptamers has the same length.
[0040] According to one embodiment of the present invention, the plurality of L-aptamers is a library, and each member of the library has the same 5' and 3' nucleic acid sequences and a different core sequence.
[0041] According to one embodiment of the present invention, the method further comprises constructing an additional aptamer library, wherein each member of the library has identical 5' and 3' nucleic acid sequences and is randomized by up to 60% compared to the sequence of the isolated L-nucleic acid aptamer.
[0042] According to one embodiment of the present invention, the method further comprises synthesizing a plurality of L-aptamers before step (a).
[0043] According to one embodiment of the invention, the synthesis comprises error-prone PCR.
[0044] According to one embodiment of the present invention, the error-prone PCR comprises using an error-prone polymerase.
[0045] According to one embodiment of the present invention, the core sequence comprises a random or semi-random sequence.
[0046] According to an embodiment of the present invention, the polymerase comprises Sulfolobus solfataricus P2 DNA polymerase IV (DPO4) or a polymerase having an amino acid sequence at least 80% identical to DPO4.
[0047] According to an embodiment of the present invention, the polymerase has an amino acid sequence as shown in SEQ ID NO:38 or SEQ ID NO:40.
[0048] According to an embodiment of the present invention, the thrombin-binding L-DNA aptamer comprises a sequence as shown in SEQ ID NO: 10, 14 or 28 or a sequence having at least 80% identity with SEQ ID NO: 10, 12, 14, 16, 27 or 28.
[0049] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, exemplary methods and / or materials are described below. In the event of a conflict, this specification (including definitions) shall prevail. In addition, materials, methods and / or embodiments are merely illustrative and are not intended to be necessarily restrictive.
[0050] Brief description of several accompanying drawings
[0051] Some embodiments of the present invention are described herein by way of example only with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is emphasized that the details shown are by way of example and for the purpose of illustrative discussion of embodiments of the present invention. In this regard, the description with the drawings makes it apparent to those skilled in the art how embodiments of the present invention may be implemented.
[0052] In the attached picture:
[0053] Figure 1A -B. Design of a mirror-image selection scheme. A, Schematic overview of mirror-image selection of L-DNA aptamers directly from a large randomized L-DNA library (color), which bypasses the need for chemical synthesis of mirror-image target molecules as in an indirect, selection-reflection scheme (grey). PDB source: 1PPB (native human thrombin). B, Schematic overview of the procedure in the mirror-image selection scheme: Selection begins with binding to an immobilized protein target, such as a large randomized L-DNA library of native human thrombin (e.g., about 1×10 14 different L-DNA sequences); bound L-DNA was eluted and amplified by mirror-image PCR; the amplified L-DNA pool was separated into single-stranded L-DNA for the next round; after the last round of selection, the enriched L-DNA pool was analyzed by DGGE, separated and sequenced by L-DNA sequencing by synthesis using the phosphorothioate method.
[0054] Figure 2A -C. Mirror image selection of L-DNA aptamers targeting native human thrombin. A, The progress of mirror image selection was monitored by EMSA using 200 nM of the corresponding L-DNA pool and 1 μM native human thrombin or 1 μM streptavidin, analyzed by 8% non-denaturing PAGE, and stained by SYBR Green II. B, Gel quantification results of (A), where the binding fraction was determined by ImageJ software using the band intensity of the bound L-DNA pool relative to the total lane intensity. ND, (binding) not detected. C, Re-amplification by mirror image PCR using D-Dpo4-5m with L-DNA primers, analyzed by 10% denaturing PAGE in 2.1 M to 4.2 M urea and 12% to 24% formamide, and DGGE analysis of the corresponding L-DNA pool stained with SYBR-Green II and the isolated bands L-9-1 and L-9-2.
[0055] Figure 3A -N. Characterization of selected L-DNA aptamers. A, The secondary structure of the L-9-1 aptamer predicted by Mfold, where the nucleotides originating from the randomized region are shown in blue (SEQ ID NO: 9). B, ITC analysis of the binding of the L-9-1 aptamer to native human thrombin, where Kd was measured to be 29 nM. C, Secondary structure of L-9-1t (truncated version) aptamer predicted by Mfold, where nucleotides derived from the randomized region are shown in cyan (SEQ ID NO: 10). D, ITC analysis of L-9-1t aptamer binding to native human thrombin, where K d was measured as 39 nM. E, EMSA of 200 nM Cy5-L-9-1t aptamer binding to 1 μM native human thrombin or 1 μM streptavidin (in the absence or presence of 50 units / ml DNase I) analyzed by 8% non-denaturing PAGE. F, EMSA of 35 nM Cy5-L-9-1t aptamer binding to various concentrations of native human thrombin analyzed by 8% non-denaturing PAGE. G, Gel quantification results of (f), where the binding score was determined by ImageJ software using the band intensity of the bound Cy5-L-9-1t aptamer relative to the total lane intensity. H, Secondary structure of the L-9-2 (SEQ ID NO: 13) aptamer predicted by Mfold, where nucleotides derived from the randomized region are shown in red. I, ITC analysis of L-9-2 aptamer binding to native human thrombin, where K d was measured to be 168 nM. J, Secondary structure of L-9-2t (truncated version) aptamer (SEQ ID NO: 14) predicted by Mfold, where nucleotides originating from the randomized region are shown in light green. K, ITC analysis of L-9-2t aptamer binding to native human thrombin, where K d Measured as 251 nM. L, EMSA of 200 nM Cy5-L-9-2t aptamer binding to 1 μM native human thrombin or 1 μM streptavidin (in the absence or presence of 50 units / ml DNase I) analyzed by 8% native PAGE. M, EMSA of 200 nM Cy5-L-9-2t aptamer binding to various concentrations of native human thrombin analyzed by 8% native PAGE. N, Gel quantification results of (M), where the bound fraction was determined by ImageJ software using the band intensity of the bound Cy5-L-9-2t aptamer relative to the total lane intensity.
[0056] Figure 4A-I. Detection and inhibition of native human thrombin using selected L-DNA aptamers. A, Schematic overview of the detection of native human thrombin using L-9-1t aptamer-based L-DNA aptamer sensors. B, Measured relative fluorescence of L-DNA aptamer sensors incubated with 1 μM native human thrombin for up to 48 minutes in physiological buffer alone or in physiological buffer containing 10% human serum, with an excitation wavelength of 494 nm and an emission wavelength of 518 nm, and measurements were taken every 4 min. NC1, negative control in physiological buffer alone. NC2, negative control in physiological buffer containing 10% human serum. RFU, relative fluorescence unit. Data are expressed as mean ± SD (n = 3, independent measurements). C, Thrombin concentrations measured by D-DNA and L-DNA aptamer sensors incubated with 300 nM native human thrombin for 1 h or 4 h in physiological buffer alone or in physiological buffer containing 10% human serum or 50 units / ml DNase I. Data are expressed as mean ± SD (n = 3, independent measurements). D, Schematic overview of the detection of native human thrombin using L-DNA aptamer western blot. E, Native human thrombin was separated by 15% SDS-PAGE, transferred to nitrocellulose membrane, incubated with 500nM Cy5-L-13t aptamer and scanned by Amersham Typhoon Biomolecular Imager operating in Cy5 mode. F, Streptavidin was separated by 15% SDS-PAGE, incubated with 500nM Cy5-L-13t aptamer and scanned by Amersham Typhoon Biomolecular Imager operating in Cy5 mode. G, Native human thrombin was separated by 15% SDS-PAGE, transferred to nitrocellulose membrane, incubated with monoclonal primary antibody targeting native human thrombin and Alexa Fluor 647-labeled polyclonal secondary antibody, and scanned by Amersham Typhoon Biomolecular Imager operating in Cy5 mode. M, Protein labeling. H, Schematic overview of the inhibition of native human thrombin enzymatic activity using L-DNA aptamers. I, Relative thrombin enzymatic activities of L-9-2 and L-9-2t aptamers incubated with 10 nM native human thrombin and 100 μM fluorogenic substrate benzoyl-Phe-Val-Arg-AMC in physiological buffer, where IC 50 They were measured to be 317±128 nM and 479±65 nM, respectively. Data are presented as mean±SD (n=3, independent measurements).
[0057] Figure 5A-C. Sequencing of DGGE-isolated L-DNA aptamers using the phosphorothioate method. A, Band L-9-1 was amplified by D-Dpo4-5m using L-dNTPαS and 5'-FAM-labeled L-DNA forward sequencing primer, cleaved by 2-iodoethanol, and analyzed by 10% denaturing PAGE. B, Band L-9-1 (SEQ ID NO: 9) was amplified by D-Dpo4-5m using L-dNTPαS and 5'-FAM-labeled L-DNA forward sequencing primer, cleaved by 2-iodoethanol, treated by CIP, and analyzed by 10% denaturing PAGE. C, Band L-9-2 (SEQ ID NO: 13) was amplified by D-Dpo4-5m using L-dNTPαS and 5'-FAM-labeled L-DNA forward sequencing primer, cleaved by 2-iodoethanol, treated by CIP, and analyzed by 10% denaturing PAGE. Ambiguous nucleotide positions are marked with asterisks, with the most likely substituted nucleotides (A and G) or deletions (-) indicated.
[0058] Fig. 6A -B. Exclusion of incorrect sequences from the sequencing results of band L-9-2 by DGGE. A, Schematic overview of exclusion of incorrect sequences by DGGE, since the correct sequence should be identical to the T m B, Natural versions of the eight most likely L-DNA aptamer sequences (DL-9-2-1 to DL-9-2-8, calculated T m Indicated in brackets) were amplified by native PCR using FastPfu Fly DNA polymerase with D-DNA primers and the L-DNA pool from R0 and R9, analyzed by 10% denaturing PAGE in 2.1 M to 4.2 M urea and 12% to 24% formamide, and stained by SYBR-Green II, where the co-migration of DL-9-2-7 and band L-9-2 is indicated by the blue dashed straight line.
[0059] Fig. 7A-N. Reselection and optimization of L-DNA aptamers from a partially randomized L-DNA library. A, Schematic overview of the reselection and optimization of L-DNA aptamers from a partially randomized L-DNA library, in which 34 nucleotides were partially randomized at a frequency of 10% based on the L-9-2 aptamer. B, The progress of mirror selection was monitored by EMSA using 200nM of the corresponding L-DNA pool and 1μM native human thrombin or 1μM streptavidin, analyzed by 8% non-denaturing PAGE and stained by SYBRGreen II. C, Gel quantification results of (b), in which the binding fraction was determined by ImageJ software using the band intensity of the bound L-DNA pool relative to the total lane intensity. ND, (binding) not detected. D, Re-amplification by mirror PCR using D-Dpo4-5m with L-DNA primers, analyzed by 10% denaturing PAGE in 2.1M to 4.2M urea and 12% to 24% formamide, and DGGE analysis of the corresponding L-DNA pool and isolated band L-13 stained by SYBR-Green II. E, Sequencing chromatogram of band L-13 by D-Dpo4-5m with L-dNTPαS and 5'-FAM labeled L-DNA sequencing primers after native CIP treatment (with two mutations highlighted in yellow). F, Secondary structure of L-13 aptamer (SEQ ID NO:27) predicted by Mfold, with nucleotides derived from the reselection shown in red and two mutations (adenosine to cytidine) shown. G, ITC analysis of L-13 aptamer binding to native human thrombin, with K d was measured at 22 nM. H, Secondary structure of the L-13t (truncated version) aptamer (SEQ ID NO: 28) predicted by Mfold, where the nucleotides derived from the reselection are shown in pink and two mutations (adenosine to cytidine) are shown. I, ITC analysis of the binding of the L-13t aptamer to native human thrombin, where K d was measured as 34 nM. J, EMSA of 35 nM Cy5-L-13t aptamer binding to various concentrations of native human thrombin analyzed by 8% non-denaturing PAGE. K, Gel quantification results of (J), where the binding fraction was determined by ImageJ software using the band intensity of the bound Cy5-L-13t aptamer relative to the total lane intensity. L, Schematic overview of the inhibition of native human thrombin enzymatic activity using the reselected L-DNA aptamers. M, Relative thrombin enzymatic activities of L-13 and L-13t aptamers incubated with 10 nM native human thrombin and 100 μM fluorescent substrate benzoyl-Phe-Val-Arg-AMC in physiological buffer, where IC 50Measured as 27 ± 3 nM and 46 ± 4 nM, respectively. Data are expressed as mean ± SD (n = 3, independent measurements). N, schematic overview of anticoagulation using L-DNA aptamers. Prothrombin time measured with 2.5 μM native versions of L-9-1t, L-13t and L-9-1t (DL-9-1t) aptamers in the presence of 50% (v / v) human plasma. NC, negative control with physiological buffer alone. Data are expressed as mean ± SD (n = 3, independent measurements, two-tailed unpaired Student's t-test).
[0060] Description of the Specific Embodiments of the Invention
[0061] The present invention, in some embodiments thereof, relates to methods of selecting L-nucleotide aptamers and methods of sequencing the same.
[0062] Before explaining at least one embodiment of the invention in detail, it should be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
[0063] Mirror image aptamers made from chiral inverted nucleic acids are nuclease resistant and exceptionally biostable. Despite their diagnostic and therapeutic potential, only a few mirror image aptamers have been selected by indirect selection schemes, such as 'select-reflex', mainly because the vast majority of biologically important target molecules, such as large proteins, cannot be chemically synthesized and correctly folded. The inventors have now developed a 'mirror image selection' scheme for the discovery of L-DNA aptamers selected directly from large randomized L-DNA libraries using mirror image molecule tools (see Figure 1A The present inventors performed iterative rounds of enrichment of L-DNA sequences that bind to native human thrombin and D-amino acid polymerase chain reaction (PCR) amplification combined with denaturing gradient gel electrophoresis (DGGE) for separation and L-DNA sequencing by synthesis for determination of enriched L-DNA aptamer sequences, and identified several high affinity L-DNA aptamers that bind to thrombin (e.g. Figure 1B exemplified in ).
[0064] While further putting the present invention into practice, the inventors designed sensors and inhibitors based on selected L-DNA aptamers that function in a physiologically relevant nuclease-rich environment, even in the presence of human serum that rapidly degrades D-DNA aptamers (e.g., Figure 4B -C, 4H-I and 7N).
[0065] The realization of direct, mirror-image selection schemes for L-DNA aptamers greatly expands the applications of mirror-image biology systems to fully unleash the potential of mirror-image aptamers as biostable biosensors, therapeutic agents, and basic research tools. The biostability of L-DNA conjugates and mirror-image molecular tools will also make the system fully resistant to degradation by contaminating nucleases and proteases, especially for low-purity target molecules and cell- and tissue-based selection.
[0066] Therefore, according to a first aspect of the present invention, there is provided a method for screening a plurality of L-nucleic acid aptamers for L-nucleic acid aptamers having binding affinity to a target molecule, comprising:
[0067] (a) contacting the plurality of L-nucleic acid aptamers with the target molecule under conditions in which the target-bound L-nucleic acid aptamers are selectively captured from the plurality of L-nucleic acid aptamers;
[0068] (b) amplifying the L-nucleic acid aptamer of the target-binding L-nucleic acid aptamer to generate an amplified double-stranded L-nucleic acid oligonucleotide;
[0069] (c) The amplified double-stranded L-nucleic acid oligonucleotides are separated using an electrophoresis-based method, thereby screening a variety of L-nucleic acid aptamers.
[0070] As used herein, the term "aptamer" refers to a nucleic acid molecule that displays specific binding affinity for a target molecule, wherein such target is different from the polynucleotide to which the aptamer sequence binds by a mechanism that primarily relies on Watson / Crick base pairing.
[0071] The phrase "L-aptamer" refers to an aptamer comprising at least one L-deoxyribonucleotide or at least one L-ribonucleotide. According to a specific embodiment, at least 50% of the nucleotides of the L-aptamer are L-nucleotides. In yet another embodiment, all nucleotides of the L-aptamer are L-nucleotides. Here, it is also intended that instead of deoxyribose or ribose, other sugars may form the sugar component of the nucleotide. In addition, the use of nucleotides with further modifications at position 2', such as NH2, OMe, OBt, O alkyl, NH alkyl, and the use of natural and non-natural nucleobases, such as, for example, isocytidine, isoguanosine ...
[0072] L-nucleic acid aptamer can be double-stranded or single-stranded. Usually, it is single-stranded L-nucleic acid, yet, due to its primary sequence, it can form a definite secondary structure, and therefore also forms a tertiary structure. In the secondary structure, a large amount of L-nucleic acid has a double-stranded part.
[0073] The target molecule can be a peptide (e.g., a naturally occurring or synthetic peptide), a protein (or a portion thereof), a sugar (e.g., a monosaccharide or a polysaccharide), a lipid, a small molecule (e.g., less than 1500 Daltons), a mixture of cell membrane fragments, or a microorganism. In some embodiments, the target molecule does not include any nucleotide or polynucleotide molecule.
[0074] According to a specific embodiment, the target molecule is a protein (or a part thereof).
[0075] The binding affinity (Kd) of the aptamer for the target molecule is preferably less than 2000 nM, less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, and even less than 50 nM as measured by EMSA (in the absence of serum).
[0076] As mentioned, the aptamers selected according to the methods described herein specifically (or selectively) bind to their targets, i.e., the aptamers bind to the target molecule with an affinity at least 10, 20, or even 50 times greater than to a non-target molecule of the same type. Thus, for example, if an aptamer selectively binds to a protein (e.g., human thrombin), it binds to thrombin with an affinity at least 10 times greater than to a protein of similar size (e.g., bovine thrombin).
[0077] The method for selecting candidate aptamers begins by contacting a plurality of L-aptamer candidates with a target molecule under conditions that selectively capture target-bound L-aptamers from among the plurality of L-aptamer candidates.
[0078] Synthesis of L-aptamer candidates:
[0079] The L-aptamer candidate for nucleic acid comprises any number of candidate for nucleic acid, for example at least 10, at least 100, at least 1000, and it has different sequences separately.Candidate's L-aptamer can all have the same length or can have different lengths.The exemplary length of L-aptamer is 20-500 nucleotide length, 20-400 nucleotide length, 20-300 nucleotide length, 20-200 nucleotide length and 20-100 nucleotide length.
[0080] The chemical synthesis of L-aptamers can be implemented by solid phase synthesis using L-DNA phosphoramidite chemistry as known in the art. Candidate L-aptamers can be purified after synthesis using methods known in the art, including but not limited to non-denaturing polyacrylamide gel electrophoresis to remove L-aptamers that are prone to aggregation.
[0081] In one embodiment, the multiple L-aptamer candidate is a member of a library, each member of which has identical 5' and 3' nucleotide sequences and different (e.g., random) core sequences. The core sequence can be 10-100 nucleotides in length, 10-80 nucleotides in length, 10-70 nucleotides in length, 10-60 nucleotides in length, 10-50 nucleotides in length, 10-40 nucleotides in length, or 10-30 nucleotides in length.
[0082] The preparation of such combinatorial libraries is described, for example, in Conrad, RC, Giver, L., Tian, Y. and Ellington, AD, 1996, Methods Enzymol., Vol. 267, 336-367.
[0083] In order to effectively increase the members of the library with the same 5' and 3' sequences, chemically synthesized aptamers can be amplified by error-prone PCR, whereby the 5' and 3' ends (which are primer binding sites) are kept constant by virtue of the primers used during the PCR reaction, and the core is susceptible to error-prone PCR. In one embodiment, the error-prone PCR utilizes an error-prone polymerase (e.g., Dpo4 or Taq DNA polymerase). In another embodiment, a high-fidelity polymerase (e.g., Pfu DNA polymerase) is used and amplification conditions that promote error insertions (e.g., addition of Mn 2+ ).
[0084] It will be appreciated that the amount of variation in the pool of L-DNA candidates can be controlled during chemical synthesis by doping the wild-type nucleotide with each of the other three L-DNA nucleotides.
[0085] Furthermore, in principle, RNA libraries can also be generated from double-stranded DNA by means of a suitable DNA-dependent RNA polymerase, such as T7 RNA polymerase, if a T7 promoter has been previously included. 15 A library of 1 or more DNA or RNA molecules. Each molecule from the library has a different sequence and therefore a different three-dimensional structure.
[0086] Capture target-bound L-aptamer
[0087] In order to distinguish between L-aptamers that bind to a target with high affinity and L-aptamers that bind to a target with lower affinity, the target can be used as bait to capture aptamers that bind to the target. This is used to enrich the pool for L-aptamers that bind to the target.
[0088] In order to capture the aptamer binding target, the target molecule can be immobilized on a solid support. Exemplary solid supports include, but are not limited to, laminated graphene, carbon nanotubes, fullerenes, and particles. Examples of materials that can be used to make particles include, but are not limited to, silica beads, polystyrene beads, latex beads, and can include metal colloids. According to a specific embodiment, the particles are magnetic particles. The target molecule can be immobilized on the solid support surface by hydrophobic interaction, electrostatic interaction, covalent bond, coordination bond, or non-covalent intermolecular action (such as biotin-streptavidin).
[0089] In other embodiments, the target molecule can be attached to a readable marker, such as a fluorescent marker, so that the signal from the target molecule bound by the aptamer can be read and recorded using, for example, FACS. In other embodiments, the target molecule may not contain a readable marker. In such cases, the aptamer in the library to be screened may have certain scaffolds (e.g., hairpin scaffolds and displacement strands) that change its structure after the aptamer binds to the target molecule. The conformational changes induced by the target molecule binding can then generate a readable signal to be recorded (e.g., due to FRET interactions).
[0090] It should be understood that before capturing the L-aptamer binding to the target molecule, the candidate pool can be pre-enriched by at least one round of negative selection (i.e., depleting the pool of sequence candidates that non-specifically bind to non-targets). For example, selection can be implemented for bead-immobilized human serum to reduce the number of aptamers that non-specifically bind to non-targets.
[0091] Amplification of target-bound L-aptamers
[0092] Once the target-binding aptamers are separated from the non-target-binding aptamers, they can be amplified using a mirror-image PCR reaction.
[0093] As used herein, the term "mirror image" refers to an isomer that is a mirror image of a natural material in terms of chirality.
[0094] The phrase "mirror PCR reaction" refers to a polymerase chain reaction that incorporates L-nucleotides into the amplified sequence.
[0095] Mirror PCR reactions typically use a mirror polymerase, which is a D-amino acid polymerase that is a mirror image of a natural polymerase (i.e., an L-type polymerase). The terms "mirror polymerase" and "D-type polymerase" or "D-amino acid polymerase" are used interchangeably. For example, "D-Dpo4" refers to a D-type Dpo4 polymerase that is a mirror image of a natural L-type Dpo4 polymerase.
[0096] Polymerases particularly suitable for use in the present invention include D-ASFV pol X, D-Dpo4, D-Taq polymerase, D-Pfu polymerase and functional variants thereof.
[0097] Dpo4 (Sulfolobus solfataricus P2 DNA polymerase IV) is a thermostable polymerase that can synthesize DNA at 37°C. Its error rate is 8×10 -3 Up to 3×10 -4 It is a polymerase that can replace Taq for multi-cycle PCR reactions. The length of its amino acid sequence is within the range of current chemical synthesis technology.
[0098] Taq polymerase is a thermostable polymerase that remains active at the temperature at which DNA denaturates. The optimum temperature for Taq is between 75°C and 80°C, and the half-life at 92.5°C is about 2 hours.
[0099] Pfu polymerase is found in Pyrococcus furiosus, and its function in microorganisms is to replicate DNA during cell division. It is superior to Taq in that it has 3'-5' exonuclease activity and can cleave nucleotides added by mistake on the extended chain during DNA synthesis. The mismatch rate of commercial Pfu is about 1 in 1.3 million.
[0100] As used herein, the term "functional variant" refers to a variant comprising one or more (e.g., 1-5, 1-10 or 1-15, in particular, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15 or even more) amino acid substitutions, deletions or additions in the amino acid sequence of a wild-type enzyme, and the variant substantially retains the biology of the wild-type enzyme. For example, 50%, 60%, 70%, 80% or 90% or more of the biological activity of the wild-type enzyme is retained. A "functional variant" can be a naturally occurring variant, or an artificial variant, such as a variant obtained by site-directed mutagenesis, or a variant produced by a genetic recombination method.
[0101] In a preferred embodiment of the present invention, the mirror nucleic acid polymerase may comprise an affinity tag to facilitate purification and reuse of the protein, such as a polyhistidine tag (His-tag or His tag), a polyarginine tag, a glutathione-S-transferase tag, and the like.
[0102] A specific functional variant of the Dpo4 protein is Dpo4-5m, which comprises amino acid mutations at 5 positions. In one embodiment, the Dpo4 protein comprises at least one, two, three, four or each of the following mutations: C31S, S86C, N123A, S207A and S313A.
[0103] The amino acid sequence of Dpo4-5m polymerase may comprise the sequence shown in SEQ ID NO:38.
[0104] In another embodiment, the Dpo4-5m polymerase comprises a Sso7d domain fused to the C-terminus of Dpo4-5m (an exemplary sequence is set forth in SEQ ID NO:40).
[0105] In one embodiment, mirror PCR is performed in a buffer of 50 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 1 mM DTT and 50 mM KCl.
[0106] The present invention also provides D-ASFV pol X, the sequence of which is shown in SEQ ID NO: 39, wherein except for achiral glycine, all other amino acids are D-amino acids.
[0107] In some embodiments, the mirror nucleic acid, mirror nucleic acid template, mirror nucleic acid primer, and mirror dNTP / rNTP are in L-form, and the mirror nucleic acid polymerase is in D-form.
[0108] Herein, the nucleic acid replication reaction can be performed in only one cycle or in multiple cycles. This can be determined by those skilled in the art according to actual needs.
[0109] As used herein, the term "plurality" refers to at least two. For example, "plurality of cycles" refers to 2 or more cycles, such as 3, 4 or 10 cycles.
[0110] As used herein, the term "replication" includes obtaining one or more copies of a target DNA in the presence of a DNA template and dNTPs; and also obtaining one or more copies of a target RNA in the presence of a DNA template and rNTPs (this process may also be referred to as RNA "transcription"). In the process of nucleic acid replication, the template and primer are usually DNA. If the target nucleic acid is DNA, dNTPs should be added to the reaction system; if the target nucleic acid is RNA, rNTPs should be added to the reaction system.
[0111] In a particularly preferred embodiment, the reaction is carried out in a buffer of 50 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 1 mM DTT and 50 mM KCl.
[0112] Should be understood that, if L-nucleic acid aptamer is RNA aptamer, then should implement reverse transcription reaction before the amplification step by polymerase chain reaction.The library enriched after the first round of selection can be used for the selection of renewal round, so that the molecule enriched in the first round of selection has the opportunity to obtain advantage by selection and amplification again, and enters the next round of selection, with even more sub-molecules.The merged thing of enrichment occurs in this way, and its member is then separated using the method based on electrophoresis, as further described below.
[0113] For multiple rounds of selection, the amplified aptamer sequence (which is double-stranded) is converted to a single-stranded nucleic acid sequence before adding the target.
[0114] The method for obtaining single-stranded nucleic acid is known in the art and the present invention contemplates using any of these methods. In a specific embodiment, an intron is used to interrupt a reverse primer (e.g., Sp18 intron) so that the PCR product contains two chains of unequal length. Denaturing PAGE can then be used to separate the two chains (see Examples section below).
[0115] In another embodiment, a binding moiety is used to modify one of the reverse primers (e.g., biotin) and the double-stranded DNA is captured by a reagent that specifically binds to the binding moiety (e.g., streptavidin-coated beads). The strands without the binding moiety can be eluted using NaOH, while the strands with the binding moiety remain attached to the reagent.
[0116] The present invention contemplates at least 3 rounds of selection, amplification, and conversion to single-stranded aptamers, at least 4 rounds of selection, amplification, and conversion to single-stranded aptamers, at least 5 rounds of selection, amplification, and conversion to single-stranded aptamers, at least 6 rounds of selection, amplification, and conversion to single-stranded aptamers. In one embodiment, no more than 10 rounds of selection, amplification, and conversion to single-stranded aptamers are performed. In yet another embodiment, no more than 15 rounds of selection, amplification, and conversion to single-stranded aptamers are performed.
[0117] The enrichment of those binding to the target in the pool of L-aptamers can be monitored using methods known in the art. Such methods include the electromobility shift assay (EMSA).
[0118] As mentioned, after the L-aptamer pool is sufficiently enriched, the resulting aptamers are further purified using an electrophoresis-based method, as further described below.
[0119] Isolation of amplified L-nucleic acid oligonucleotides
[0120] Electrophoresis-based methods for isolating target-binding aptamers include, but are not limited to, native PAGE; denaturing PAGE; denaturing gradient gel electrophoresis (DGGE); constant denaturing gel electrophoresis (CDGE), capillary electrophoresis, and time temperature gradient gel electrophoresis (TTGE).
[0121] According to a specific embodiment, the electrophoresis-based method for separating candidate target-binding aptamers is DGGE.
[0122] Denaturation / temperature gradient gel electrophoresis (DGGE / TGGE): This is a method that relies on detecting changes in electrophoretic mobility in response to minor sequence changes. One of these methods, called "denaturing gradient gel electrophoresis" (DGGE), is based on the observation that slightly different sequences will exhibit different local melting patterns when electrophoretically resolved on gradient gels. In this way, variants can be distinguished because the difference in the melting characteristics of homoduplexes that are different in terms of single nucleotides relative to heteroduplexes can detect the presence of SNPs in the target sequence because their electrophoretic mobility changes accordingly. The fragment to be analyzed, usually a PCR product, is "clamped" at one end by a long GC base pair (30-80) to completely denature the target sequence without completely dissociating the chain. The attachment of the GC "clamp" to the DNA fragment increases the portion of mutations that can be identified by DGGE (Abrams et al., Genomics 7:463-475, 1990). Attaching a GC clamp to one primer is critical to ensuring that the amplified sequence has a low dissociation temperature (Sheffield et al., Proc. Natl. Acad. Sci., 86:232-236, 1989; and Lerman and Silverstein, Meth. Enzymol., 155:482-501, 1987). A variation of this technique has been developed using a temperature gradient (Wartell et al., Nucl. Acids Res., 18:2699-2701, 1990), and the method can also be applied to RNA: RNA duplexes (Smith et al., Genomics 3:217-223, 1988).
[0123] Limitations to the use of DGGE include the requirement that the denaturation conditions must be optimized for each type of DNA to be tested. In addition, the method requires specialized equipment to prepare the gel and maintain the required high temperature during electrophoresis. For each sequence to be tested, the associated costs of synthesizing the tail on an oligonucleotide are also major considerations. In addition, DGGE requires long run times. The long run time of DGGE is shortened in a variant of DGGE, which is called constant denaturing gel electrophoresis (CDGE) (Borrensen et al., Proc. Natl. Acad. Sci. USA 88: 8405, 1991). CDGE requires gels to be run under different denaturing conditions to achieve high efficiency in detecting SNPs.
[0124] A technique similar to DGGE, called temperature gradient gel electrophoresis (TGGE), uses a thermal gradient rather than a chemical denaturing gradient (Scholz, et al., Hum. Mol. Genet. 2:2155, 1993). TGGE requires the use of specialized equipment that can generate a temperature gradient oriented perpendicularly to the electric field. TGGE can detect mutations in relatively small DNA fragments, so scanning large gene segments requires the use of multiple PCR products before running the gel.
[0125] After separation by electrophoresis, the isolated L-DNA aptamers can be sequenced using methods known in the art.
[0126] Exemplary methods for sequencing L-DNA aptamers include, but are not limited to, L-DNA chemical sequencing; L-DNA phosphorothioate sequencing; L-DNA dideoxy sequencing; L-DNA Ion Torrent sequencing; L-DNA Illumina sequencing; and L-DNA nanopore sequencing.
[0127] High-throughput methods can include technologies for rapid sequencing of large numbers of nucleic acids, including next-generation technologies such as massively parallel signature sequencing (MPSS; Polony sequencing; 454 pyrosequencing; Illumina (Solexa) sequencing; SOLiD sequencing; ion torrent semiconductor sequencing; DNA nanoball sequencing; Heliscope single molecule sequencing; single molecule real-time (SMRT) sequencing, or other methods such as nanopore DNA sequencing; tunneling current DNA sequencing; sequencing by hybridization; sequencing with mass spectrometry; microfluidics Sanger sequencing; microscopy-based technologies; RNAP sequencing; in vitro viral high-throughput sequencing.
[0128] Automated dideoxy terminator sequencing reactions were performed on the isolated L-nucleotide aptamers using either a dye-terminator (unlabeled primer and labeled dideoxynucleotide) or a dye-primer (labeled primer and unlabeled dideoxynucleotide) cycle sequencing protocol. For the dye-terminator reaction, a PCR reaction was performed using an unlabeled PCR primer, followed by a sequencing reaction in the presence of one of the primers, a deoxynucleotide, and a labeled dideoxynucleotide mixture. For the dye-primer reaction, a PCR reaction was performed using a PCR primer conjugated to a universal or reverse primer (one in each direction), followed by a sequencing reaction in the presence of four separate mixtures (corresponding to A, G, C, T nucleotides), each of which contained a labeled primer specific for the universal or reverse sequence and the corresponding unlabeled dideoxynucleotide.
[0129] Pyrosequencing TMAnalysis (Pyrosequencing, Inc. Westborough, MA, USA): This technique is based on the hybridization of sequencing primers with single-stranded, PCR-amplified DNA templates in the presence of DNA polymerase, ATP sulfurylase, luciferase and apyrase, as well as adenosine 5' phosphosulfate (APS) and luciferin substrates. In the second step, the first of four deoxynucleoside triphosphates (dNTPs) is added to the reaction, and if the deoxynucleoside triphosphate is complementary to the base in the template strand, the DNA polymerase catalyzes the incorporation of the deoxynucleoside triphosphate into the DNA strand. Each incorporation event is accompanied by the release of pyrophosphate (PPi), which is equimolar to the amount of the incorporated nucleotides. In the final step, ATP sulfurylase converts PPi quantitatively into ATP in the presence of adenosine 5' phosphosulfate. The ATP drives the luciferin mediated by luciferase to oxyluciferin, which produces visible light in an amount proportional to the amount of ATP. The light generated by the luciferase catalysis reaction is detected by a charge-coupled device (CCD) camera and displayed on a pyrogram. TM Each light signal is proportional to the number of nucleotides incorporated.
[0130] Phosphorothioate sequencing: Phosphorothioate sequencing can be implemented by performing a mirror PCR reaction (e.g., using D-Dpo4-5m) in which one of the L-dNTPs is replaced by the corresponding L-dNTPαS. The product is mixed with a solution containing 2-iodoethanol. In one embodiment, a phosphatase (e.g., calf intestinal phosphatase-CIP) is first used to remove 3'-monophosphate from 2-iodoethanol-cleaved DNA fragments before running on a denaturing sequencing gel. More information about phosphorothioate sequencing can be found in Fan, C., et al. Nat. Biotechnol. 39: 1548-1555 (2021) (the contents of which are incorporated herein by reference).
[0131] Once the sequence is obtained, the L-DNA aptamers can be chemically synthesized and their binding activity to their corresponding targets can be verified.
[0132] Once a lead candidate sequence is obtained, it can be used as a starting point for creating a new library and thereby identifying additional candidates with improved affinity / specificity. The lead sequence can be partially randomized (e.g., 1-60% randomized. In one embodiment, the lead candidate sequence is mutated with 10% randomization (about 3.3% for each base other than the original base), so the doping rate can be between 1% and 60%.
[0133] If necessary, the reagents for isolating the L-DNA aptamer of the present invention may be presented in a kit. The kit may be accompanied by instructions for use.
[0134] According to a specific embodiment, the kit comprises:
[0135] (i) calf intestinal phosphatase (CIP);
[0136] (ii) L-deoxyribonucleotide triphosphate (L-dNTP) or modified L-dNTP; and / or
[0137] (iii) (iii) a polymerase capable of adding one or more L-nucleotides to the 3' end of the first L-nucleic acid.
[0138] Modified L-dNTPs include L-deoxynucleoside α-thiotriphosphates.
[0139] The aptamers of the invention can be used in various methods to assess the presence or level of a biomarker in a biological sample, such as a target biological entity, such as a protein, sugar, cell, or microvesicle. Aptamers function as binding agents to assess the presence or level of a cognate target molecule. Thus, in various embodiments of the invention involving diagnosis, prognosis, or therapeutic diagnosis, one or more aptamers of the invention are configured in a ligand-target based assay, wherein one or more aptamers of the invention are contacted with a selected biological sample, wherein one or more aptamers associate or bind to their target molecule. The aptamers of the invention are used to identify candidate biosignatures based on the biological sample being assessed and the biomarker being detected.
[0140] L-nucleic acid aptamers discovered by the methods of the present invention include those having a nucleic acid sequence as shown in SEQ ID NO: 10, 12, 14, 16, 27 or 28. In one embodiment, the L-nucleic acid aptamer has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 10, 14 or 28. In another embodiment, the L-nucleic acid aptamer has a sequence as shown in SEQ ID NO: 10, 12, 14, 16, 27 or 28, wherein up to 10 nucleotides of the sequence are mutated, wherein the position of the mutation is a single-stranded region of the aptamer (as predicted by computational analysis such as Mfold). In one embodiment, the single-stranded region is Figure 3A , 3C , 3H, 3J, 7F or the single-stranded region shown in 7H.
[0141] The aptamers described herein can be attached to a detectable moiety or label.
[0142] Suitable labels include, but are not limited to, magnetic labels, fluorescent moieties, enzymes, chemiluminescent probes, metal particles, non-metallic colloidal particles, polymeric dye particles, pigment molecules, pigment particles, electrochemically active substances, semiconductor nanocrystals or other nanoparticles (including quantum dots or gold particles), fluorophores, quantum dots, or radioactive labels. Protein labels include green fluorescent protein (GFP) and its variants (e.g., cyan fluorescent protein and yellow fluorescent protein); and luminescent proteins, such as luciferase, as described below. Radioactive labels include, but are not limited to, radioisotopes (radionuclides), such as 3H, 11C, 14C, 18F, 32P, 35S, 64Cu, 68Ga, 86Y, 99Tc, 111In, 123I, 124I, 125I, 131I, 133Xe, 77Lu, 211At, or 213Bi. Fluorescent labels include, but are not limited to, rare earth chelates (e.g., europium chelates), rhodamine; fluoresceins, including, but not limited to FITC, 5-carboxyfluorescein, 6-carboxyfluorescein; rhodamines, including, but not limited to TAMRA; dansyl; Lissamine; cyanine; phycoerythrin; Texas Red; Cy3, Cy5, dapoxyl, NBD, Cadcade Yellow, dansyl, PyMPO, pyrene, 7-diethylaminocoumarin 3-carboxylic acid and other coumarin derivatives, Marina Blue TM 、PacificBlue TM Cascade Blue TM , 2-Anthracenesulfonyl, PyMPO, 3,4,9,10-Perylene-tetracarboxylic acid, 2,7-difluorofluorescein (Oregon Green TM 488-X), 5-carboxyfluorescein, Texas Red TM-X, Alexa Fluor 430, 5-carboxytetramethylrhodamine (5-TAMRA), 6-carboxytetramethylrhodamine (6-TAMRA), BODIPY FL, bimane and Alexa Fluor 350, 405, 488, 500, 514, 532, 546, 555, 568, 594, 610, 633, 647, 660, 680, 700 and 750, and derivatives thereof, among others. See, e.g., "The Handbook--A Guide to Fluorescent Probes and Labeling Technologies", 10th edition, available on the Internet at probes(dot)invitrogen(dot)com / handbook. The fluorescent marker can be one or more of FAM, dRHO, 5-FAM, 6FAM, dR6G, JOE, HEX, VIC, TET, dTAMRA, TAMRA, NED, dROX, PET, BHQ, Gold540 and LIZ.
[0143] L-nucleic acid aptamers can be labeled directly or indirectly using conventional techniques, for example, by attaching a label to an aptamer via biotin-streptavidin (e.g., a synthetic biotinylated aptamer that is then able to bind to a streptavidin molecule that is itself conjugated to a detectable label; a non-limiting example is phycoerythrin-conjugated streptavidin (SAPE)). Chemical coupling methods using multi-step procedures include coupling of biotinylation, trinitrophenol (TNP) or digoxin, using, for example, succinimidyl esters of these compounds. Biotinylation can be accomplished, for example, using D-biotinyl-N-hydroxysuccinimide. The succinimide group reacts effectively with amino groups at pH values above 7, and preferably between about pH 8.0 and about pH 8.5. Alternatively, the aptamer is not labeled, but is then contacted with a labeled secondary antibody after the primary antibody binds to the target antigen.
[0144] Various enzyme-substrate labels can also be used for combining with L-aptamers. Such enzyme-substrate labels are commercially available (e.g., U.S. Patent number 4,275,149). The enzyme usually catalyzes the chemical changes of chromogenic substrates, which can be measured using various techniques. For example, the enzyme can catalyze the color change of substrates, which can be measured by spectrophotometry. Alternatively, the enzyme can change the fluorescence or chemiluminescence of substrates. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidases such as horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase, glucoamylase, lysozyme, sugar oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Examples of enzyme-substrate combinations include, but are not limited to, horseradish peroxidase (HRP) using catalase as a substrate, wherein the catalase oxidizes a dye precursor (e.g., o-phenylenediamine (OPD) or 3,3',5,5'-tetramethylbenzidine hydrochloride (TMB)); alkaline phosphatase (AP) using p-nitrophenyl phosphate as a chromogenic substrate; and β-D-galactosidase (β-D-Gal) using a chromogenic substrate (e.g., p-nitrophenyl-β-D-galactosidase) or a fluorogenic substrate 4-methylumbelliferyl-β-D-galactosidase.
[0145] L-aptamers can be connected to substrates, such as planar substrates. Planar arrays generally contain addressable positions (e.g., pads, addresses or micro-positions) of biomolecules in array form. The size of the array will depend on the composition and end use of the array. An array containing 2 different molecules to thousands can be prepared. Typically, the array comprises two to as many as 100,000 or more molecules, depending on the end use and manufacturing method of the array. The microarray used together with the present invention includes at least one biomolecule identifying or capturing a biomarker present in a target biosignature, for example, microRNA or other biomolecules or vesicles constituting a biosignature. In some arrays, a variety of substrates are used, which have different or identical compositions. Therefore, a planar array can include multiple smaller substrates.
[0146] The present inventors have shown that the use of calf intestinal phosphatase (CIP) following iodoethanol cleavage of DNA fragments facilitates sequencing of oligonucleotides containing L-deoxynucleoside α-thiotriphosphates.
[0147] Therefore, according to yet another aspect of the present invention, there is provided a method for sequencing a purified L-DNA molecule, comprising:
[0148] (a) treating a sample comprising purified L-DNA molecules with a phosphatase (e.g., CIP) under conditions that remove the 3'-monophosphate from the L-DNA molecules: and
[0149] (b) subjecting the sample to phosphorothioate sequencing, thereby sequencing the purified L-DNA molecules.
[0150] As used herein, the term "about" refers to ± 10%.
[0151] The terms "comprises," "comprising," "includes," "including," "having" and conjugations thereof mean "including but not limited to."
[0152] The term "consisting of" means "including and limited to."
[0153] The term "consisting essentially of" means that a composition, method, or structure may include additional ingredients, steps, and / or parts, but only if the additional ingredients, steps, and / or parts do not materially change the basic and novel characteristics of the claimed composition, method, or structure.
[0154] As used herein, the singular forms "a", "an", and "the" include plural references unless the context clearly indicates otherwise. For example, the term "compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0155] Throughout this application, various embodiments of the present invention may be presented in the form of a range. It should be understood that the description in the form of a range is only for convenience and brevity, and should not be interpreted as a hard limit to the scope of the invention. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and individual values within the range. For example, a description of a range such as 1-6 should be considered to have specifically disclosed sub-ranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., and individual numbers within the range such as 1, 2, 3, 4, 5 and 6. This applies regardless of the width of the range.
[0156] Whenever a numerical range is indicated herein, it is meant to include any stated numeral (fractional or integral) within the indicated range. The phrases "range between" the first indicated numeral and the second indicated numeral and "range from" the first indicated numeral "to" the second indicated numeral "are used interchangeably herein and are meant to include the first and second indicated numerals and all fractions and integrals therebetween.
[0157] As used herein, the term "method" refers to manners, means, techniques and procedures for accomplishing a given task, including but not limited to those manners, means, techniques and procedures known to practitioners in the fields of chemistry, pharmacology, biology, biochemistry and medicine or those readily developable by such practitioners from known manners, means, techniques and procedures.
[0158] When reference is made to a particular sequence listing, such reference should be understood to also include sequences that substantially correspond to the complementary sequence thereof while including minor sequence variations caused by, for example, sequencing errors, cloning errors or other changes resulting in base substitutions, base deletions or base additions, as long as the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.
[0159] It should be understood that any sequence identification number (SEQ ID NO) disclosed in this application can refer to a DNA sequence or an RNA sequence, depending on the context in which the SEQ ID NO is mentioned, even if the SEQ ID NO is only presented in a DNA sequence format or an RNA sequence format. Similarly, although some sequences are presented in an RNA sequence format (e.g., U for uracil is listed), depending on the actual type of molecule being described, it can refer to the sequence of an RNA molecule containing a dsRNA, or the sequence of a DNA molecule corresponding to the RNA sequence shown. In any case, both DNA and RNA molecules having the disclosed sequences and any alternatives are contemplated.
[0160] It should be understood that certain features of the invention described in the context of separate embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment for the sake of brevity may also be provided individually or in any suitable sub-combination or in any other described embodiment of the invention as appropriate. Certain features described in the context of various embodiments should not be considered essential features of those embodiments unless the embodiment is invalid without those elements.
[0161] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples. Example
[0162] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
[0163] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are fully explained in the literature. General references are provided throughout this document.
[0164] Material
[0165] All L-DNA oligonucleotides (Table 1A and Table 1B below) are synthesized on H-8 oligonucleotide synthesizer (K&ALaborgeraete, Germany). All D-DNA oligonucleotides (Table 1A-B below) are ordered from Genewiz (Jiangsu, China). L-deoxynucleoside phosphoramidites are purchased from ChemGenes (MA, US). Hexaethylene glycol spacer (Sp18) phosphoramide is purchased from Glen Research (VA, US). Fluorescein (FAM) and cyanine 5 (Cy5) phosphoramide and 4-(4-dimethyl-aminophenylazo) benzoic acid (DABCYL) and monophosphate controlled pore glass (CPG) are purchased from Ruibiotech (Beijing, China). All D-DNA and L-DNA oligonucleotides are purified by HPLC or denaturation PAGE before use. L-deoxynucleoside triphosphates (L-dNTP) and L-deoxynucleoside α-thiotriphosphates (L-dNTPαS) were synthesized from L-deoxynucleoside (ChemGenes, MA, US). 1 D-dNTPαS was purchased from TriLink Biotechnologies Inc. (CA, US). L-Dpo4-5m with an N-terminal His6 tag was expressed in Escherichia coli strain BL21 and cultured as described in the literature. 2 FastPfu Fly DNA polymerase was purchased from TransGen Biotech (Beijing, China). D-Dpo4-5m was synthesized and folded according to the previously reported method, except that an automated peptide synthesizer was used and norleucine (Nle) was replaced by methionine (Met). 2,3. 2-Iodoethanol was purchased from Aladdin Bio-Chem Technology Co., Ltd. (Shanghai, China). Plasma-derived natural human α-thrombin and natural bovine α-thrombin were purchased from Haematologic Technologies (VT, US). Streptavidin, calf intestinal alkaline phosphatase (CIP) and DNase I were purchased from New England Biolabs (MA, US). Human serum was purchased from ZhongKeChenYuBiotech (Beijing, China). Monoclonal primary antibodies targeting natural human thrombin and Alexa Fluor 647-labeled polyclonal secondary antibodies were purchased from Abcam (UK). ExRed was purchased from Beijing Zoman Biotech (Beijing, China). NHS-activated magnetic beads and SYBR-Green II were purchased from Thermo Fisher Scientific (MA, US). Benzoyl-Phe-Val-Arg-AMC (AMC, 7-amino-4-methylcoumarin) was purchased from Sigma-Aldrich (MO, US).
[0166] Table 1A - DNA sequences
[0167]
[0168]
[0169] Table 1B - L-DNA sequences used for reselection from partially randomized L-DNA libraries
[0170]
[0171] L-DNA library preparation
[0172] A 30 nt randomized region of a D-DNA or L-DNA library with a total length of 65 nt was synthesized at a molar ratio of D- or L-dA, dC, dG, dT phosphoramidites of 1.5:1.25:1.15:1 to achieve approximately equal coupling efficiency 4 As mentioned in the literature 5As described in , non-denaturing polyacrylamide gel electrophoresis (PAGE) purification was performed to remove DNA that is prone to aggregation. Briefly, 5 nmol of the synthetic D-DNA or L-DNA library was loaded onto a 1 mm × 200 mm × 550 mm plate and separated by PAGE, which consisted of a denatured top portion (1 mm × 200 mm × 50 mm) and a non-denaturing bottom portion (1 mm × 200 mm × 500 mm), wherein the denatured top portion contained 7 M urea, 8% acrylamide in 0.5× Tris-borate-EDTA (TBE), and the non-denaturing bottom portion contained 10% acrylamide, 10 mM Mg(OAc)2 in 0.5× TBE. The gel was run at 10 W (constant power) for 6 h and stained by SYBR-Green II. The fastest migrating 1 / 3 of the separated bands was purified by the 'crush and soak' method. 6 Purification. About 165 pmol of the native-PAGE-purified library (with about 1×10 14 different sequences), wherein the reverse primer contains a poly d(A) modified by Sp18 20 Tailing to generate PCR products with different chain lengths for analysis by denaturing PAGE 7 Strand separation was performed. The native and mirror PCR programs were set to 86°C for 3 minutes (initial denaturation); 86°C for 30 seconds, 50°C for 1 minute, and 65°C for 2 minutes, 15 cycles; 65°C for 5 minutes (final extension). The 65nt forward strand was separated from the 85nt Sp18-modified reverse strand by 10% denaturing PAGE in 7M urea and used as the starting D-DNA or L-DNA library for aptamer selection. Selection of D-DNA or L-DNA aptamers targeting native human thrombin
[0173] According to the manufacturer's instructions (Thermo Fisher Scientific, MA, US), the magnetic beads coupled to natural human thrombin are prepared from the magnetic beads activated by N-hydroxysuccinimide (NHS). In brief, 300 μl of natural human thrombin at a concentration of 0.1 mg / ml is mixed with 3mg NHS-activated magnetic beads in coupling buffer (20mM HEPES-NaOH, 150mM NaCl, 5% glycerol, pH 7.4). The coupling reaction is carried out at room temperature for 2h, and then quenched with the 3M ethanolamine of pH 9.0. After coupling, beads are resuspended in 300 μl of selection buffer (20mM HEPES-NaOH, 150mM NaCl, 5mM KCl, 2mM MgCl2, 1mM CaCl2, 0.05% (v / v) Tween-20, pH 7.4). For round 1 (R1), approximately 600 pmol (with approximately 1×10 14 About 3.6×10 different sequences 14The D-DNA or L-DNA library of 100 μl of 100 μl of 2 ... The D-DNA or L-DNA recovered are used as templates for carrying out natural or mirror image PCR amplification by L-Dpo4-5m or D-Dpo4-5m, to generate the D-DNA or L-DNA pool for the next round. Each natural or mirror image PCR cycle number of the selection round is determined based on the result of 10 μ l scale PCR. As shown in Tables 2 and 3, the amount of DNA pools is gradually reduced from the approximately 600 pmol in R1 to the approximately 50 pmol in R6 (for D-DNA pools), and from the approximately 600 pmol in R1 to the approximately 30 pmol in R9 (for L-DNA pools). The volume of the magnetic beads coupled with natural human thrombin is gradually reduced from the 100 μ l in R1 to the 10 μ l in R6 (for D-DNA pools), and from the 100 μ l in R1 to the 3 μ l in R9 (for L-DNA pools). Washing steps gradually increased from 3 10-second washes in R1 to 6 10-minute washes in R6 (for the D-DNA pool), and from 3 10-second washes in R1 to 8 10-minute washes in R9 (for the L-DNA pool).
[0174] Table 2 - Conditions used for D-DNA aptamer selection
[0175]
[0176]
[0177] Table 3 - Conditions used for L-DNA aptamer selection
[0178]
[0179] Electrophoretic mobility shift assay (EMSA)
[0180] D-DNA or L-DNA pools and D-DNA or L-DNA aptamers were heated to 85°C for 5 minutes in selection buffer and slowly cooled to 25°C over 10 minutes, then mixed with native human thrombin or streptavidin in selection buffer containing 10% (v / v) glycerol. The mixtures were incubated at room temperature for 30 minutes and analyzed by 8% native PAGE in 1× running buffer (20 mM HEPES-NaOH, 50 mM NaOAc, 5 mM KOAc, 2 mM Mg(OAc)2, 1 mM CaCl2, pH 7.4) (for D-DNA or L-DNA pools, D-6, Cy5-L-9-1t and Cy5-L-13t aptamers) or by 10% native PAGE in 1× running buffer (for Cy5-L-9-2t aptamers) in which 5% (v / v) glycerol was added to both the gel and the running buffer. The gel was run at 150 V (constant voltage) for 1-2 h, stained with SYBR-Green II, and scanned by Amersham Typhoon Biomolecular Imager (Cytiva, US) running in Cy2 mode (for D-DNA or L-DNA pools and D-6 aptamer) or Cy5 mode (for Cy5-labeled L-DNA aptamer). Gel quantification was performed by ImageJ software, where the dissociation constant (K d ) were calculated by fitting the binding fraction to a sigmoidal model using KaleidaGraph software (Synergy Software, PA, US).
[0181] Denaturing gradient gel electrophoresis (DGGE)
[0182] D-DNA or L-DNA pools and D-DNA or L-DNA aptamers were amplified by native or mirror PCR using L-Dpo4-5m or D-Dpo4-5m and the D-DNA or L-DNA primers listed in Table 1A, where the forward primer contained a GC-rich region (GC-clamp) to prevent complete melting of the double-stranded PCR product during DGGE8 8. Native or mirror PCR products were purified by 3% sieving agarose gel electrophoresis and mixed with 2× loading buffer (100 mM Tris-HCl, 10 mM EDTA, 30% glycerol, pH 7.0) and separated by 7.5% polyacrylamide gel (for D-DNA pool) or 10% polyacrylamide gel (for L-DNA pool) (which consisted of a linear denaturant gradient of 2.1 M urea, 12% (v / v) formamide (top) to 4.2 M urea and 24% (v / v) formamide (bottom) in 1× Tris-acetate-EDTA (TAE). Gels were run at 100 V for 6 h at 60° C. (constant temperature) (for D-DNA pool) or at 75 V for 13 h at 60° C. (for L-DNA pool). For DGGE separation of D-DNA or L-DNA aptamer sequences, 500 ng of native or mirror-image PCR products were separated by DGGE, stained with SYBR-Green II, separated by cutting the gel on a 254 nm UV transilluminator, and by the ‘crush and soak’ method. 6 The aptamers were purified and re-amplified by native or mirror PCR using L-Dpo4-5m or D-Dpo4-5m and the D-DNA or L-DNA primers listed in Table 1A. To exclude incorrect sequences from the L-9-2 band sequencing results, the native versions of the eight most likely L-DNA aptamer sequences in band L-9-2 (DL-9-2-1 to DL-9-2-8, Figure 6B and Table 4 below) were amplified by native PCR using FastPfu Fly DNA polymerase and D-DNA primers, separated by DGGE, stained by SYBR-Green II, and scanned by Amersham Typhoon Biomolecular Imager operating in Cy2 mode. Melting temperature (T m ) Using the nearest neighbor thermodynamic model via OligoCalc 9 The default parameters are calculated.
[0183] Table 4 - D-DNA oligonucleotides used for DGGE analysis and calculated melting temperatures (T m )
[0184]
[0185]
[0186] High-throughput sequencing of selected D-DNA aptamers
[0187] The R6 D-DNA pool and the D-6 band separated by DGGE were amplified by native PCR using L-Dpo4-5m and the D-DNA primers listed in Table 1A. The PCR products were purified by 2.5% agarose and sequenced on the Illumina HiSeq system (Illumina, CA, US). The original Illumina reads were processed and sorted according to abundance using the Galaxy server (www (dot) usegalaxy (dot) org).
[0188] Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS)
[0189] MALDI-TOF MS was used to analyze the dephosphorylation of L-DNA by CIP. Approximately 100 ng of 3'-monophosphate-labeled L-DNA oligonucleotides (Table 1A) were treated with 20 units of CIP, incubated for 1 h at 37°C in 1× CutSmart buffer (New England Biolabs, MA, US), desalted by C18 spin columns (Thermo Fisher Scientific, MA, US), and analyzed by MALDI-TOF MS (Applied Biosystems 4800plus, CA, US) in positive linear mode.
[0190] L-DNA aptamer sequencing
[0191] Using the 5'-FAM-labeled forward sequencing primer and the unlabeled reverse primer listed in Table 1A, four separate PCR reactions were performed in which one of the L-dNTPs was replaced by the corresponding L-dNTPαS 10 The L-DNA aptamer separated by DGGE was amplified by mirror PCR using D-Dpo4-5m in a 5′-FAM-labeled PCR product (instead of PCR). The 5′-FAM-labeled PCR product was purified by 10% denaturing PAGE in 7M urea and dissolved in 10mM Tris-HCl, pH 7.4, to a final concentration of about 20ng / μl. For each sequencing reaction, 5μl of 5′-FAM-labeled L-DNA was mixed with 5μl of lysis solution containing 2% (v / v) 2-iodoethanol in ddH2O, then heated to 95°C for 3 minutes and quickly placed on ice. To remove 3′-monophosphate from 2-iodoethanol-cleaved DNA fragments, each sequencing reaction was treated with 5 units of CIP, incubated in 1× CutSmart buffer at 37°C for 1h, and then mixed with 10μl of 2× loading buffer containing 95% formamide and 10mM EDTA. The samples were loaded on a 0.4 mm × 340 mm × 300 mm plate and processed according to a previously reported method. 10Analysis was performed by 10% denaturing PAGE in 7 M urea.
[0192] Isothermal Titration Calorimetry (ITC)
[0193] Native human thrombin, native bovine thrombin, and streptavidin in storage buffer were dialyzed against physiological buffer (20 mM HEPES-NaOH, 150 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2, pH 7.4) at 4°C for 16 h. D-DNA and L-DNA aptamers were equilibrated in physiological buffer by ultrafiltration, then heated to 85°C for 5 minutes and slowly cooled to 25°C over 10 minutes. MicroCal iTC 200 Microcalorimeter (GE Healthcare, UK), with 7 μM to 20 μM of native human thrombin, native bovine thrombin or streptavidin in the reaction chamber and 70 μM to 200 μM of D-DNA or L-DNA aptamer in the syringe at 25 ° C and 750 rpm stirring for ITC. To measure the heat of dilution, 70 μM to 200 μM of D-DNA or L-DNA aptamer was injected into a physiological buffer without protein. MicroCal Origin software (GE Healthcare, UK) was used for data fitting.
[0194] L-DNA aptamer sensor
[0195] D-DNA or L-DNA aptamer sensors containing 250 nM 5'-FAM-labeled fluorophore chains, 750 nM 3'-DABCYL-labeled quencher chains and 500 nM aptamer chains based on D-6 or L-9-1t aptamers (Table 1A) were incubated with 300 nM native human thrombin in physiological buffer alone or in physiological buffer containing 10% (v / v) human serum at 37°C for 1 h or 4 h. Relative fluorescence was measured by Varioskan Flash system (Thermo Fisher Scientific, MA, US) with an excitation wavelength of 494 nm and an emission wavelength of 518 nm. A standard curve was drawn using 0, 125, 250, 500 or 1000 nM native human thrombin and relative fluorescence was measured after incubation in physiological buffer at 37°C for 1 h. The change in relative fluorescence unit (ΔRFU) relative to the background (RFU measured with D-DNA or L-DNA aptamer sensor in physiological buffer alone) was used for data fitting. For measurements in physiological buffer containing 10% (v / v) human serum, a standard curve was prepared using 0, 250, 500, 1000 or 2000 nM native human thrombin, and relative fluorescence was measured after incubation in physiological buffer containing 10% human serum at 37°C for 1 h. To evaluate the biostability of D-DNA and L-DNA aptamer sensors, the sensors were incubated at 37°C in physiological buffer containing 10% human serum for up to 24 h (for D-DNA aptamer sensors), or at 37°C in physiological buffer containing 83% (v / v) human serum for up to 24 h (for D-DNA aptamer sensors) or up to 30 d (720 h) (for L-DNA aptamer sensors). The samples were mixed with 2× loading buffer containing 95% formamide and 10 mM EDTA and quickly placed at -20°C before analysis by 10% denaturing PAGE in 7 M urea. Gel quantification was performed using ImageJ software, where the half-life (t 1 / 2 ) were calculated by fitting the relative band intensities to an exponential decay model using KaleidaGraph software (Synergy Software, PA, US).
[0196] L-DNA Aptamer Western Blot
[0197] The Cy5-L-13t aptamer was heated to 85°C for 5 minutes in physiological buffer and slowly cooled to 25°C over 10 minutes. Native human thrombin was separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane in 1× transfer buffer (25mM Tris, 192mM glycine, 20% (v / v) methanol, pH 8.3). The membrane was incubated in 1× blocking buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, 25mg / ml bovine serum albumin, 0.05% (v / v) Tween-20, pH 7.4) at room temperature for 1h and incubated with 500nM Cy5-L-13t aptamer in selection buffer for 1h at room temperature. After incubation, the membranes were washed 5 times with selection buffer (5 min each wash) and scanned by an Amersham Typhoon Biomolecular Imager operating in Cy5 mode. Conventional western blotting was performed using antibodies according to the manufacturer's instructions (Abcam, UK).
[0198] L-DNA aptazyme inhibitors
[0199] The L-DNA aptamer was heated to 85°C for 5 minutes in physiological buffer, slowly cooled to 25°C over 10 minutes, to which native human thrombin was added to a final concentration of 10 nM. The mixture was incubated at room temperature in physiological buffer for 30 minutes, followed by the addition of 100 μM fluorescent substrate benzoyl-Phe-Val-Arg-AMC. Relative fluorescence was measured by a Varioskan Flash system with an excitation wavelength of 350 nm and an emission wavelength of 450 nm. The relative thrombin enzymatic activity was determined, with the ΔRFU at 0 minutes set to 0, the ΔRFU of the negative control in physiological buffer alone set to 100%, and the ΔRFU at 16 minutes used to calculate the relative thrombin enzymatic activity. The half maximal inhibitory concentration (IC 50 ) was calculated by fitting the relative thrombin enzymatic activity to the sigmoidal model using KaleidaGraph software.
[0200] L-DNA aptamer coagulation assay
[0201] Human plasma was obtained from healthy volunteers. D-DNA and L-DNA aptamers were heated to 85°C for 5 minutes in 180 μl of physiological buffer, slowly cooled to 25°C for annealing over 10 minutes, and incubated with 180 μl of human plasma (to a final concentration of 2.5 μM for D-DNA and L-DNA aptamers) at room temperature for up to 10 minutes. Prothrombin time was measured by Stago STA R Max automatic coagulation analyzer (Stago, France) according to the manufacturer's instructions.
[0202] result
[0203] Validation and optimization of a selection protocol for identifying L-DNA aptamers directly from large randomized L-DNA libraries
[0204] Although Dpo4-5m has been shown to efficiently amplify short DNA sequences 7,8 , but it has not yet been tested in the amplification of large randomized DNA libraries. Here, approximately 1 × 10 14 A large randomized D-DNA library of 10 different sequences was constructed, in which 30 randomized nucleotides were flanked by two constant regions for primer binding. The ability of L-Dpo4-5m to amplify large randomized D-DNA libraries was demonstrated and was also demonstrated against commercially available native human thrombin purified from plasma (Materials and Methods), for which high affinity D-DNA aptamers had been previously selected. 30,31 ) were subjected to iterative rounds of selection. The progress of the selection was monitored by electrophoretic mobility shift assay (EMSA), which accesses the overall binding score of the sequence pool during each selection round. 32 . After 6 rounds of selection, about 70% of the D-DNA pool bound 1 μM native human thrombin but not 1 μM streptavidin. Next, the 6th round (R6) D-DNA pool was sequenced by high-throughput sequencing, which revealed the enrichment of multiple DNA sequences, although the most abundant sequence accounted for only about 1.1% of the total reads.
[0205] To determine whether D-DNA sequences of similar lengths can be separated based on different melting temperatures, DGGE was performed to analyze natural PCR products from R4 to R6, as well as from R0 before selection. Although no clear bands were observed in R0 and R4, single bands began to appear in R5, and the number and intensity of bands increased in R6. Next, a single band (D-6) was isolated from R6, which accounted for approximately 1.7% of the total lane fluorescence intensity of R6. Band D-6 was amplified by natural PCR using L-Dpo4-5m and D-DNA primers, and the PCR product was analyzed by another DGGE, which revealed a major band accounting for approximately 35% of the total lane fluorescence intensity. The band was recovered from DGGE and its composition was analyzed by high-throughput sequencing, which revealed that a single sequence accounted for approximately 45% of the total reads (249,272 of 554,081 reads). In fact, the same sequence (D-6) was also found in the R6 pool before DGGE separation, but only accounted for about 0.8% of the R6 reads (ranked 4). Therefore, although the D-6 sequence was quite rare in the R6 pool (revealed by DGGE about 1.7%, and by high-throughput sequencing about 0.8%), it became predominant after DGGE separation and amplification by L-Dpo4-5m PCR (revealed by DGGE about 35%, and by high-throughput sequencing about 45%).
[0206] Next, the cleavage was performed using the phosphorothioate method with D-deoxynucleoside α-thiotriphosphate (D-dNTPαS) and cleavage by 2-iodoethanol. 33 (It has recently been used for L-DNA sequencing by synthesis 13 ) was sequenced for band D-6. Due to band doubling (a phenomenon mainly attributed to the presence of 3'-hydroxyl and 3'-monophosphate groups in the cleaved DNA fragments 34 ), the sequencing results were quite ambiguous. To solve this problem, 2-iodoethanol-cleaved DNA fragments were treated with calf intestinal alkaline phosphatase (CIP). Most of the band doubles disappeared after CIP treatment, which may be due to the removal of 3'-monophosphate from the cleaved DNA fragments, and thus the sequence of band D-6 was easily determined. 35 Prediction of the secondary structure of the D-6 aptamer revealed that it contains a loop region that fits into the consensus sequence of previously identified D-DNA aptamers targeting native human thrombin. 30 Finally, the D-DNA aptamer D-6 was prepared by solid phase oligonucleotide synthesis with a dissociation constant (K d) binds to native human thrombin as determined by isothermal titration calorimetry (ITC) in physiological buffer (20 mM HEPES-NaOH, 150 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2, pH 7.4). In addition, the D-6 aptamer forms a stable complex with native human thrombin as revealed by EMSA, which can be digested by DNase I as expected.
[0207] Mirror image selection of L-DNA aptamers targeting native human thrombin
[0208] Approximately 1 × 10 14 A large randomized L-DNA library of different sequences was prepared, in which 30 randomized nucleotides were flanked by two constant regions for primer binding, just like the D-DNA library. The L-DNA library was amplified by mirror-image PCR using D-Dpo4-5m and L-DNA primers. As in the natural system, the progress of mirror-image selection was monitored by EMSA ( Figure 2A After 9 rounds of selection, about 70% of the L-DNA pool bound to 1 μM native human thrombin but not to 1 μM streptavidin ( Figure 2A , B). DGGE was performed to analyze the mirror-image PCR products from R5 to R9, and from R0 before selection ( Figure 2C Although no clear bands were observed in R0 and R5, a single band began to appear in R6, with the number and intensity of the bands increasing from R7 to R9 ( Figure 2C Two bands (L-9-1 and L-9-2) were separated from R9, accounting for approximately 1.7% and approximately 1.6% of the total lane fluorescence intensity of R9, respectively ( Figure 2C In two separate reactions, the bands were amplified by mirror PCR using D-Dpo4-5m and L-DNA primers, and the mirror PCR products were analyzed by another DGGE, both revealing major bands that accounted for approximately 18% and approximately 12% of the corresponding total lane fluorescence intensity, respectively ( Figure 2C ).
[0209] To sequence the enriched L-DNA aptamers, band L-9-1 was isolated for sequencing using the phosphorothioate method with L-deoxynucleoside α-thiotriphosphate (L-dNTPαS) and cleavage by 2-iodoethanol. 13 L-DNA was sequenced while being synthesized. Similar to the results of phosphorothioate sequencing in natural systems, the sequencing results were blurred again due to band doubling ( Figure 5A ). 2-iodoethanol-cleaved L-DNA fragments were subjected to CIP, and unexpectedly, it was found that CIP treatment significantly improved L-DNA sequencing results ( Figure 5B), which is probably through the removal of 3'-monophosphate in L-DNA via the previously unreported cross-chiral dephosphorylation activity of CIP. Therefore, the sequence of band L-9-1 was easily determined.
[0210] In addition, band L-9-2 was also sequenced using the phosphorothioate method, and it was observed that three nucleotide positions in the central region of the sequenced aptamer caused read ambiguity even by CIP treatment (which may be due to contaminating sequences) and generated eight most likely L-DNA aptamer sequences ( Figure 5C and Table 4). It is reasonable to assume that by comparing the migration of potential aptamer sequences, DGGE can be used to exclude incorrect sequences, because the correct sequence should co-migrate with band L-9-2 at the same melting temperature ( Fig. 6A ). Therefore, the natural versions (to save costs and mirror enzymes) of the eight most likely L-DNA aptamer sequences in band L-9-2 (DL-9-2-1 to DL-9-2-8, Table 4) were screened by DGGE to exclude incorrect sequences. It was observed that only the DL-9-2-7 sequence co-migrated with band L-9-2 ( Figure 6B ), indicating that DL-9-2-7 and band L-9-2 may share the same sequence. Therefore, the sequence of band L-9-2 was separated by the first DGGE ( Figure 2C ), using a combination of L-DNA sequencing by synthesis using the phosphorothioate method and a second DGGE to exclude incorrect sequences ( Figure 6B ).
[0211] Characterization of selected L-DNA aptamers
[0212] To evaluate the binding affinity of the sequenced L-DNA aptamers to native human thrombin, L-DNA aptamer L-9-1 was prepared by solid phase oligonucleotide synthesis ( Figure 3A ), which has a K of 29 nM d Binding to native human thrombin as determined by ITC in physiological buffer ( Figure 3B ), which is consistent with the K d (27 nM). The L-9-1 aptamer was truncated from 65 nt to 36 nt based on its secondary structure predicted by Mfold ( Figure 3C ), and the truncated aptamer (L-9-1t) was observed to bind with only slightly reduced affinity (K d =39nM, Figure 3D) binds to native human thrombin. Meanwhile, no binding was detected between the L-9-1t aptamer and streptavidin and between the native version of L-9-1t (DL-9-1t) aptamer and native human thrombin, indicating that the binding between the L-9-1t aptamer and native human thrombin is target-specific and chiral-specific. Further shortening the L-9-1t aptamer from 36 nt to 32 nt by truncating a portion of the stem region resulted in an approximately 3-fold decrease in affinity (K d =111 nM, which may be due to the destabilization of the secondary structure of the aptamer. In addition, the 5'-cyanine 5 (Cy5)-labeled L-9-1t (Cy5-L-9-1t) aptamer had a K of 21 nM. d It forms a stable complex with native human thrombin as determined by EMSA and is resistant to DNase I digestion as expected ( Figure 3E -G).
[0213] L-DNA aptamer L-9-2 was also prepared by solid phase oligonucleotide synthesis ( Figure 3H ), which has a K of 168 nM d Binding to native human thrombin as determined by ITC in physiological buffer ( Fig. 3I The L-9-2 aptamer was then truncated from 65 nt to 38 nt based on its secondary structure predicted by Mfold ( Figure 3J ), and the truncated aptamer (L-9-2t) was observed to bind with only slightly reduced affinity (K d =251nM, Figure 3K ) binds to native human thrombin. Meanwhile, no binding was detected between the L-9-2t aptamer and streptavidin and between the native version of L-9-2t (DL-9-2t) aptamer and native human thrombin, indicating that the binding between the L-9-2t aptamer and native human thrombin is target-specific and chiral-specific. In addition, the 5'-Cy5-labeled L-9-2t (Cy5-L-9-2t) aptamer binds to native human thrombin with a K of 355 nM. d Binds to native human thrombin as determined by EMSA ( Figure 3L -N) and, as expected, were resistant to DNase I digestion ( Figure 3L In addition, a truncated version of L-9-2-1 (L-9-2-1t) aptamer was prepared by solid phase oligonucleotide synthesis based on the DGGE-predicted contaminating sequence (DL-9-2-1) from R9, and it was observed that the binding affinity of L-9-2-1t aptamer to native human thrombin was about 1 / 5 of that of L-9-2t aptamer (K d =1337nM).
[0214] To further evaluate the target specificity of the L-DNA aptamers, the binding affinity of the L-9-1t and L-9-2t aptamers to native bovine thrombin was measured. Bovine thrombin exhibits approximately 85% sequence identity with native human thrombin. 38 It was observed that L-9-1t and L-9-2t aptamers had K values of 1027 nM and 426 nM, respectively. d Binding to native bovine thrombin showed a binding affinity reduced to about 1 / 26 and about 1 / 1.7 compared to native human thrombin (39 nM and 251 nM, respectively). These results indicate that the L-9-1t aptamer binds to native human thrombin more tightly than to native bovine thrombin, while the L-9-2t aptamer binds to both with similar affinity.
[0215] L-DNA aptamer sensor
[0216] To demonstrate the potential practical application of thrombin-binding L-DNA aptamers, the high-affinity thrombin-binding L-DNA aptamer L-9-1t was hybridized with an L-DNA fluorophore chain with 5′-labeled fluorescein (FAM) and an L-DNA quencher chain with 3′-labeled 4-(4-dimethyl-aminophenylazo)benzoic acid (DABCYL), both of which were hybridized with the L-9-1t aptamer to form a stable L-DNA duplex. 39 ) combination, synthesis of structure-switching L-DNA aptamer sensor ( Figure 4A Upon binding to native human thrombin, the L-9-1t aptamer undergoes a structural transition, releasing the quencher chain and resulting in a relative fluorescence increase with a linear response in the range of approximately 125-1000 nM ( Figure 4B ). In contrast, the L-DNA aptamer sensor did not respond to the addition of 1 μM streptavidin or 1 μM native bovine thrombin, which is consistent with the ITC results.
[0217] To evaluate the effect of serum enzymes on the biostability and thrombin sensing ability of the L-DNA aptamer sensor, the L-DNA aptamer sensor was incubated in a physiological buffer containing 10% (v / v) human serum, which provides a physiologically relevant nuclease-rich environment. The L-DNA aptamer sensor responded to the addition of native human thrombin in a physiological buffer containing 10% human serum, with a linear response in the range of approximately 250-2000 nM ( Figure 4B At the same time, a natural structural conversion sensor (D-DNA aptamer sensor) was constructed based on the D-DNA aptamer D-6. Next, 300 nM (final concentration) of natural human thrombin was added to a sample containing D-DNA or L-DNA aptamer sensors and 10% human serum or 50 units / ml DNase I (one of the main nucleases in serum). 41After incubation in physiological buffer containing 10% human serum for 1 h, the D-DNA and L-DNA aptamer sensors measured thrombin concentrations of 416 ± 62 nM and 457 ± 72 nM, respectively, which were comparable to those measured in physiological buffer alone (334 ± 59 nM and 299 ± 12 nM, respectively, Figure 4C However, after incubation in physiological buffer containing 10% human serum for 4 h, the D-DNA aptamer sensor measured a thrombin concentration of 784 ± 91 nM, while the L-DNA aptamer sensor measured a thrombin concentration of 375 ± 54 nM ( Figure 4C ). In addition, after incubation in physiological buffer containing 50 units / ml DNase I for 1 h and 4 h, the D-DNA aptamer sensor measured thrombin concentrations of 1219 ± 57 nM and 984 ± 52 nM, respectively, while the L-DNA aptamer sensor measured thrombin concentrations of 334 ± 58 nM and 251 ± 34 nM, respectively ( Figure 4C ).
[0218] The error-prone measurement of the D-DNA aptasensor but not the L-DNA aptasensor might be attributed to the degradation of the D-DNA aptasensor by serum enzymes or DNase I, which causes the premature release of the FAM fluorophore and the DABCYL quencher, which is consistent with the estimated half-life (t) of about 1.7 h for the D-DNA aptasensor incubated in physiological buffer containing 10% human serum as determined by denaturing polyacrylamide gel electrophoresis (PAGE). 1 / 2 ) were largely consistent. To further verify the biostability of the L-DNA aptamer sensor, the sensor was incubated in a physiological buffer containing 83% human serum, and after incubation for up to 30 days (720 h), no significant degradation of the L-DNA aptamer sensor was observed by denaturing PAGE, while the D-DNA aptamer sensor was significantly degraded with an estimated t of about 2.1 h. 1 / 2 This is largely consistent with previous studies of other D-DNA aptamers in human serum. 3,42 .
[0219] L-DNA Aptamer Western Blot
[0220] To further explore the potential practical applications of L-DNA aptamers that bind thrombin, the L-13t aptamer (which was selected and optimized in the "Reselection and Optimization of L-DNA Aptamers from Partially Randomized L-DNA Libraries" section described below) was applied to a proof-of-concept western blotting experiment based on L-DNA aptamers to detect native human thrombin ( Figure 4D6 ng to 180 ng of native human thrombin were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), then transferred to a nitrocellulose membrane and incubated with 500 nM Cy5-L-13t aptamer at room temperature for 1 h ( Figure 4E ). A fluorescent band consistent with the molecular weight of native human thrombin (about 36 kDa) was detected, with a detection limit of <6 ng ( Figure 4F In a control experiment, we analyzed 6 ng to 180 ng of streptavidin by SDS-PAGE, transferred it to a nitrocellulose membrane, and incubated it with 500 nM Cy5-L-13t aptamer. No clear band was observed at the expected molecular weight of streptavidin (approximately 18 kDa) ( Figure 4F In contrast, 6 ng to 180 ng of native human thrombin was analyzed by conventional Western blotting using a mouse monoclonal primary antibody targeting native human thrombin and an Alexa Fluor 647-labeled (with similar excitation and emission wavelengths to Cy5) goat anti-mouse IgG polyclonal secondary antibody, and a fluorescent band consistent with the molecular weight of native human thrombin (approximately 36 kDa) was detected ( Figure 4G ).
[0221] L-DNA aptazyme inhibitors
[0222] Next, in the presence of 100 μM benzoyl-Phe-Val-Arg-7-amino-4-methylcoumarin (AMC), a fluorescent substrate for thrombin, 44 ) in a physiological buffer solution to test the inhibition of thrombin enzymatic activity by L-DNA aptamers L-9-1 and L-9-2 binding to thrombin ( Figure 4H The L-9-2 aptamer inhibited the enzymatic activity of thrombin with a half maximal inhibitory concentration (IC 50 ) was measured to be 317±128( Fig. 4I ), and its K determined by ITC d (168nM, Fig. 3I ) were largely consistent. In contrast, the R0 L-DNA pool before selection did not inhibit thrombin enzymatic activity at concentrations up to 8 μM. The inhibition of thrombin enzymatic activity by a truncated aptamer (L-9-2t) was also measured. A slightly higher IC 50 479±65nM( Fig. 4I ), which is consistent with its K determined by ITC d (251nM, Figure 3K However, the L-9-1 and L-9-1t aptamers did not inhibit thrombin enzymatic activity at concentrations up to 8 μM, despite their higher binding affinity (K d29nM and 39nM, respectively), indicating that the binding sites of native human thrombin targeted by L-9-1 and L-9-2 aptamers are different. In addition, the inhibition of thrombin enzymatic activity by L-9-2t aptamer was shown to be chiral specific, because the natural version of L-9-2t aptamer (DL-9-2t) did not inhibit thrombin enzymatic activity at concentrations up to 8μM.
[0223] Reselection and optimization of L-DNA aptamers from a partially randomized L-DNA library
[0224] Suboptimal binding of L-9-2 aptamer to native human thrombin (K d was measured at 168 nM) and inhibition of thrombin enzymatic activity (where IC 50 The results of this study suggest that the L-DNA aptamer may be a promising candidate for further improvement and optimization of the L-DNA aptamer for both binding and inhibition properties.
[0225] To reselect and optimize the L-9-2 aptamer, approximately 1 × 10 11 A partially randomized L-DNA library of different sequences (R10) was prepared, in which 34 nucleotides were partially randomized at a frequency of 10% based on the L-9-2 aptamer, which was flanked by two constant regions for primer binding. Next, a mirror selection was performed on the partially randomized L-DNA library targeting natural human thrombin ( Fig. 7A ). After 3 rounds of enrichment and mirror PCR amplification ( Figure 7B , C), DGGE was applied to isolate a single band (L-13) from R13, which accounted for approximately 0.2% of the total lane fluorescence intensity of R13 ( Fig.7D Band L-13 was amplified by mirror PCR using D-Dpo4-5m and L-DNA primers, and the mirror PCR product was analyzed by another DGGE, revealing a major band accounting for about 13% of the fluorescence intensity of the corresponding total lane ( Fig.7D ). L-DNA sequencing by synthesis was performed using the phosphorothioate method to determine the enriched L-DNA aptamer sequences, and the mutant sequence of the L-9-2 aptamer was identified, in which two adenosines in the partially randomized region were mutated to cytosines ( Fig. 7E ). This reselected L-DNA aptamer (L-13) had a K of 22 nM. d Binding to native human thrombin as determined by ITC in physiological buffer ( Figure 7F , G), showing an approximately 8-fold improved binding affinity to native human thrombin compared to its parent aptamer L-9-2. Based on its secondary structure predicted by Mfold, the L-13 aptamer was truncated from 68 nt to 38 nt ( Figure 7H ), and the truncated aptamer (L-13t) bound with only slightly reduced affinity (Kd =34nM, Fig.7I ) binds to native human thrombin. In addition, it was found that the 5'-Cy5-labeled L-13t (Cy5-L-13t) aptamer binds to native human thrombin with a K of 28 nM. d Forms a stable complex with native human thrombin as determined by EMSA ( Figure 7J , K).
[0226] The reselected L-13 and L-13t aptamers were tested for inhibition of thrombin enzymatic activity in a physiological buffer containing 100 μM benzoyl-Phe-Val-Arg-AMC ( Figure 7L The L-13 aptamer was measured to have an IC of 27 ± 3 nM. 50 Inhibits thrombin enzymatic activity ( Figure 7M ), and its K determined by ITC d (22nM, Figure 7G ) were largely consistent, showing about 12-fold improved inhibition of thrombin enzymatic activity compared to its parental aptamer L-9-2. In contrast, the R10 partially randomized L-DNA pool before reselection did not inhibit thrombin enzymatic activity at concentrations up to 1.4 μM. The inhibition of thrombin enzymatic activity by a truncated aptamer (L-13t) was also measured, and a slightly higher IC 50 46±4nM( Figure 7M ), and its K determined by ITC d (34nM, Fig.7I ) are largely consistent.
[0227] As a final test of the selected L-DNA aptamers and to demonstrate their clinical potential, an in vitro coagulation assay on human plasma was performed. After adding 2.5 μM L-9-1t and L-13t aptamers, the prothrombin time was measured to be approximately 4 times and approximately 2 times that of the control without L-DNA aptamer or the native version of L-9-1t (DL-9-1t) aptamer, respectively. Figure 7N ).
[0228] Although the present invention has been described in conjunction with its specific embodiments, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. It is therefore intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
[0229] Applicants intend that all publications, patents, and patent applications mentioned in this specification be incorporated herein by reference in their entirety, just as if each individual publication, patent, or patent application specifically and individually indicated when cited that it is incorporated herein by reference. In addition, the citation or identification of any reference in this application should not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
[0230] In addition, any priority documents of the present application are incorporated herein by reference in their entirety.
[0231] References
[0232] 1Nolte,A.,Klussmann,S.,Bald,R.,Erdmann,VA&Furste,JPMirror-designof L-
[0233] oligonucleotide ligands binding to L-arginine. Nat. Biotechnol. 14, 1116-1119 (1996).
[0234] 2Klussmann,S.,Nolte,A.,Bald,R.,Erdmann,VA&Furste,JPMirror-imageRNA that
[0235] binds D-adenosine. Nat. Biotechnol. 14, 1112-1115 (1996).
[0236] 3Williams, KP et al. Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc.
[0237] Natl Acad. Sci. USA 94, 11285-11290 (1997).
[0238] 4Dunn, MR, Jimenez, RM & Chaput, JCA Analysis of aptamer discovery and technology.
[0239] Nat. Rev. Chem. 1, 0076 (2017).
[0240] 5 Zhou, J. & Rossi, J. Aptamers as targeted therapeutics: current potential and challenges. Nat.
[0241] Rev. Drug Discov. 16, 181 - 202 (2017).
[0242] 6 Wang, Z., Xu, W., Liu, L. & Zhu, T. F. A synthetic molecular system capable of mirror -
[0243] image genetic replication and transcription. Nat. Chem. 8, 698 - 704 (2016).
[0244] 7 Xu, W. et al. Total chemical synthesis of a thermostable enzyme capable of polymerase
[0245] chain reaction. Cell Discov. 3, 17008 (2017).
[0246] 8 Jiang, W. et al. Mirror - image polymerase chain reaction. Cell Discov. 3, 17037 (2017). 9 Liu, X. & Zhu, T. F. Sequencing mirror - image DNA chemically. Cell Chem. Biol. 25, 1151 - 1156 (2018).
[0247] 10 Wang, M. et al. Mirror - image gene transcription and reverse transcription. Chem 5, 848 - 857 (2019).
[0249] 11 Ling, J. - J. et al. Mirror - image 5S ribonucleoprotein complexes. Angew. Chem. Int. Ed. 59,
[0250] 3724 - 3731 (2020)
[0251] 12Chen, J., Chen, M. & Zhu, T. F. Translating protein enzymes without aminoacyl-tRNA
[0252] synthetases. Chem 7, 786 - 798 (2021).
[0253] 13Fan, C., Deng, Q. & Zhu, T. F. Bioorthogonal information storage in L-DNA with a high-
[0254] fidelity mirror-image Pfu DNA polymerase. Nat. Biotechnol. 39:1548 - 1555 (2021).
[0255] 14Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA
[0256] ligands to bacteriophage T4 DNA polymerase. Science 249, 505 - 510 (1990).
[0257] 15Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific
[0258] ligands. Nature 346, 818 - 822 (1990).
[0259] 16Wilson, D. S. & Szostak, J. W. In vitro selection of functional nucleic acids. Annu. Rev.
[0260] Biochem. 68, 611 - 647 (1999).
[0261] 17Gawande, B. N. et al. Selection of DNA aptamers with two modified bases. Proc. Natl Acad.
[0262] Sci.USA 114,2898 - 2903(2017).
[0263] 18Liu, Z. X., Chen, T. J. & Romesberg, F. E. Evolved polymerases facilitate selection of fully
[0264] 2'-OMe-modified aptamers. Chem. Sci. 8, 8179 - 8182(2017).
[0265] 19Dunn, M. R., McCloskey, C. M., Buckley, P., Rhea, K. & Chaput, J. C. Generating
[0266] biologically stable TNA aptamers that function with high affinity and thermal stability. J.
[0267] Am. Chem. Soc. 142, 7721 - 7724(2020).
[0268] 20Pinheiro, V. B. et al. Synthetic genetic polymers capable of heredity and evolution. Science
[0269] 336, 341 - 344(2012).
[0270] 21Kimoto, M., Yamashige, R., Matsunaga, K.-i., Yokoyama, S. & Hirao, I. Generation of
[0271] high-affinity DNA aptamers using an expanded genetic alphabet. Nat. Biotechnol. 31 (2013).
[0273] 22Hoshika, S. et al. Hachimoji DNA and RNA: A genetic system with eight building blocks.
[0274] Science 363,884 - 887(2019).
[0275] 23Purschke, W.G., Eulberg, D., Buchner, K., Vonhoff, S. & Klussmann, S. An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc. Natl. Acad. Sci. USA 103, 5173 - 5178 (2006).
[0277] 24Sczepanski, J.T. & Joyce, G.F. Binding of a structured D-RNA molecule by an L-RNA
[0278] aptamer. J. Am. Chem. Soc. 135, 13290 - 13293(2013).
[0279] 25Umar, M.I. & Kwok, C.K. Specific suppression of D-RNA G-quadruplex–protein
[0280] interaction with an L-RNA aptamer. Nucleic Acids Res. 48, 10125 - 10141(2020).
[0281] 26Olea Jr, C., Weidmann, J., Dawson, Philip E. & Joyce, Gerald F. An L-RNA aptamer that
[0282] binds and inhibits RNase. Chem. Biol. 22, 1437 - 1441(2015).
[0283] 27Yatime, L. et al. Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA / L-DNA aptamer. Nat. Commun. 6, 6481(2015).
[0284] 28 Pech, A. et al. A thermostable D-polymerase for mirror-image PCR. Nucleic Acids Res. 45,
[0285] 3997 - 4005(2017).
[0286] 29 Muyzer, G. & Smalla, K. Application of denaturing gradient gel electrophoresis (DGGE)
[0287] and temperature gradient gel electrophoresis (TGGE) in microbial ecology. Antonie van
[0288] Leeuwenhoek 73, 127 - 141(1998).
[0289] 30 Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H. & Toole, J. J. Selection of single-
[0290] stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564 - 566(1992). 31 Tasset, D. M., Kubik, M. F. & Steiner, W. Oligonucleotide inhibitors of human thrombin
[0291] that bind distinct epitopes. J. Mol. Biol. 272, 688 - 698(1997).
[0292] 32 Dobbelstein, M. & Shenk, T. In vitro selection of RNA ligands for the ribosomal L22
[0293] protein associated with Epstein - Barr virus - expressed RNA by using randomized and cDNA -
[0294] 衍生的RNA文库。《病毒学杂志》69卷,8027 - 8034页(1995年)。
[0295] 33吉什,G.和埃克斯坦,F.基于硫代磷酸酯的DNA和RNA序列测定。
[0296] 《科学》240卷,1520 - 1522页(1988年)。
[0297] 34中马耶,K.L.,吉什,G.,埃克斯坦,F.和沃斯伯格,H.P.通过掺入脱氧核苷α - 硫代三磷酸对聚合酶链反应扩增的DNA片段进行直接测序。
[0298] 《核酸研究》16卷,9947 - 9959页(1988年)。
[0299]
[0300] 35祖克,M.Mfold核酸折叠和杂交预测网络服务器。
[0301] 《核酸研究》31卷,3406 - 3415页(2003年)。
[0302] 36小德安达,A.等人凝血酶抑制剂在体外循环期间使用效果的初步研究。
[0303] 《胸外科年鉴》58卷,344 - 350页(1994年)。
[0304] 37博德,W.等人人α - 凝血酶的精制晶体结构:相互作用 晶体结构
[0305] 与D-苯丙氨酸-脯氨酸-精氨酸氯甲基酮以及酪氨酸-脯氨酸-脯氨酸-色氨酸插入的意义
[0306] 片段。《欧洲分子生物学组织杂志》8卷,3467 - 3475页(1989年)。
[0307] 38刘,X.等人 牛凝血酶特异性的RNA适配体。《分子识别杂志》16卷,23 - 27页 (2003年)。
[0309] 39努蒂乌,R. & 李,Y.F. 结构转换信号适配体。《美国化学会志》125卷,4771 - 4778页(2003年)。
[0310] 40李,L.-L.,葛,P.,塞尔文,P.R. & 卢,Y. 使用附着铽配合物的发光适配体传感器直接检测稀释血清中的腺苷
[0311] 。《分析化学》84卷,7852 - 7856页(2012年)。
[0313] 41巴拉,G.B.等人 EDTA介导的DNases抑制保护循环游离DNA免受血样离体降解。《临床生物化学》48卷,976 - 981页(2015年)。
[0314] 42克拉奇默,C. & 利维,M. 化学修饰对适配体在血清中稳定性的影响。
[0315] 《核酸治疗》27卷,335 - 344页(2017年)。
[0316] 43Wang, Y., Li, Z. & Yu, H. Aptamer-based Western blot for selective protein recognition.
[0317] Front. Chem. 8, 870528 (2020)
[0318] 44Li, M.-L., Ren, Y.-J., Dong, M.-H. & Ren, W.-X. Design, synthesis and structural
[0319] exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors. Eur. J.
[0320] Med. Chem. 96, 122 - 138 (2015).
[0321] 45Fang, X. H. & Tan, W. H. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res. 43, 48 - 57 (2010).
[0322] 46Li, S. et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J.
[0323] Pathol. 218, 327 - 336 (2009).
[0324] 47Sczepanski, J. T. & Joyce, G. F. A cross-chiral RNA polymerase ribozyme. Nature 515,
[0325] 440 - 442 (2014).
[0326] 48Scheitl, C. P. M., Ghaem Maghami, M., Lenz, A.-K. & C. Site-specific RNA
[0327] methylation by a methyltransferase ribozyme.Nature 587,663-667(2020).
[0328] 49Chandrasekar,J.&Silverman,S.K.Catalytic DNA with phosphataseactivity.Proc.Natl
[0329] Acad.Sci.USA 110,5315-5320(2013).
[0330] 50Peplow,M.Mirror-image enzyme copies looking-glass DNA.Nature 533,303-304(2016).51Peplow,M.A Conversation with Ting Zhu.ACS Cent.Sci.4,783-784(2018).
[0331] 52Mattheakis,L.C.,Bhatt,R.R.&Dower,W.J.An in vitro polysome displaysystem for
[0332] identifying ligands from very large peptide libraries.Proc.NatlAcad.Sci.USA 91,9022- 9026(1994).
[0334] 53Roberts,R.W.&Szostak,J.W.RNA-peptide fusions for the in vitroselection of peptides
[0335] and proteins.Proc.Natl Acad.Sci.USA 94,12297-12302(1997).
[0336] 54Reuter,Jason A.,Spacek,D.V.&Snyder,Michael P.High-throughputsequencing
[0337] technologies.Mol.Cell 58,586 - 597(2015).
[0338] 55Iliuk,A.B.,Hu,L.&Tao,W.A.Aptamer in bioanalytical applications.Anal.Chem.83,
[0339] 4440 - 4452(2011).
[0340] 56Brumbt,A. et al.Chiral stationary phase based on a biostable L - RNA aptamer.Anal.Chem.
[0341] 77,1993 - 1998(2005).
[0342] 57Idili,A.,Parolo,C.,Alvarez - Diduk,R.& A.Rapid and efficient detection of the
[0343] SARS - CoV - 2 spike protein using an electrochemical aptamer - based sensor.ACS sens.6,
[0344] 3093 - 3101(2021).
Claims
1. A method for screening a plurality of L-nucleic acid aptamers for L-nucleic acid aptamers having binding affinity to a target molecule, comprising: (a) contacting the plurality of L-nucleic acid aptamers with the target molecule under conditions in which the target-bound L-nucleic acid aptamers are selectively captured from the plurality of L-nucleic acid aptamers; (b) amplifying the L-nucleic acid aptamer of the target-binding L-nucleic acid aptamer to generate an amplified double-stranded L-nucleic acid oligonucleotide; and (c) The amplified double-stranded L-nucleic acid oligonucleotides are separated using an electrophoresis-based method, thereby screening a variety of L-nucleic acid aptamers.
2. The method of claim 1, further comprising converting the amplified double-stranded L-nucleic acid oligonucleotide into a single-stranded oligonucleotide after step (b) and before step (c).
3. The method of claim 2, wherein steps (a) and (b) and the converting step are repeated at least 3 times to enrich the target-binding L-aptamer before the separation. The method of claim 3 , further comprising monitoring the enrichment of the target-bound L-aptamer.
5. The method of claim 4, wherein said monitoring is accomplished by electrophoretic mobility shift assay (EMSA).
6. The method of any one of claims 1 to 4, wherein the electrophoresis-based method is selected from the group consisting of native PAGE; denaturing PAGE; denaturing gradient gel electrophoresis (DGGE); constant denaturing gel electrophoresis (CDGE) and time temperature gradient gel electrophoresis (TTGE).
7. The method of any one of claims 1-3, wherein the electrophoresis-based method comprises DGGE.
8. The method of any one of claims 1 to 7, wherein the target molecule is selected from the group consisting of a peptide, a polypeptide, a small molecule, a carbohydrate, and a nucleic acid molecule.
9. The method of any one of claims 1 to 8, wherein the target molecule is contained in a cell or tissue.
10. The method of any one of claims 1-9, wherein the amplification utilizes a D-amino acid polymerase.
11. The method of claim 10, wherein the D-amino acid polymerase is selected from the group consisting of D-ASFV pol X, D-Taq polymerase, D-Pfu polymerase, Sulfolobus solfataricus P2 DNA polymerase IV (DPO4), a fusion protein comprising the DPO4, and a polymerase having an amino acid sequence that is at least 80% identical to the DPO4.
12. The method of claim 11, wherein the polymerase has an amino acid sequence as shown in SEQ ID NO:38 or SEQ ID NO:
40.
13. The method according to any one of claims 1 to 12, further comprising sequencing the separated member after step (c) to obtain the sequence of the L-aptamer having binding affinity to the target molecule.
14. The method of claim 13, wherein the sequencing is achieved using a method selected from the group consisting of: L-DNA chemical sequencing; L-DNA phosphorothioate sequencing; L-DNA dideoxy sequencing; L-DNA ion torrent sequencing; L-DNA Illumina sequencing; and L-DNA nanopore sequencing.
15. The method of claim 14, wherein the method is L-DNA phosphorothioate sequencing.
16. The method of claim 15, further comprising contacting said amplified double-stranded L-nucleic acid oligonucleotide with a phosphatase prior to said sequencing.
17. The method of claim 16, wherein the phosphatase comprises calf intestinal phosphatase (CIP).
18. The method of any one of claims 1 to 17, wherein each of the plurality of L-aptamers has the same length.
19. The method of any one of claims 1 to 18, wherein the plurality of L-aptamers is a library, and each member of the library has identical 5' and 3' nucleic acid sequences and a different core sequence.
20. The method of claim 13, further comprising constructing an additional aptamer library, wherein each member of the library has identical 5' and 3' nucleic acid sequences and is randomized by up to 60% compared to the sequence of the isolated L-aptamer.
21. The method of any one of claims 1 to 19, further comprising synthesizing the plurality of L-aptamers prior to step (a).
22. The method of claim 21, wherein the synthesizing comprises error-prone PCR.
23. The method of claim 22, wherein the error-prone PCR comprises using an error-prone polymerase.
24. The method of claim 19, wherein the core sequence comprises a random or semi-random sequence.
25. A kit for identifying L-nucleic acid aptamers, comprising: (i) calf intestinal phosphatase (CIP); (ii) L-deoxyribonucleotide triphosphate (L-dNTP) or modified L-dNTP; and / or (iii) a polymerase capable of adding one or more L-nucleotides to the 3' end of the first L-nucleic acid.
26. The kit of claim 25, wherein the polymerase comprises Sulfolobus solfataricus P2 DNA polymerase IV (DPO4) or a polymerase having an amino acid sequence at least 80% identical to said DPO4.
27. The kit of claim 26, wherein the polymerase has an amino acid sequence as shown in SEQ ID NO:38 or SEQ ID NO:
40.
28. A method for sequencing a purified L-DNA molecule, comprising: (a) treating a sample comprising said purified L-DNA molecules with a phosphatase under conditions which remove the 3'-monophosphate from said L-DNA molecules: and (b) subjecting the sample to phosphorothioate sequencing, thereby sequencing the purified L-DNA molecules.
29. An isolated thrombin-binding L-DNA aptamer comprising a sequence as shown in SEQ ID NO: 10, 12, 14, 16, 27 or 28 or a sequence having at least 80% identity thereto.
30. An isolated thrombin-binding L-DNA aptamer comprising a sequence as shown in SEQ ID NO: 10, 14 or 28 or a sequence having at least 80% identity thereto.
Citation Information
Patent Citations
Bovine viral diarrhea virus E0 protein amino acid and preparation method thereof
CN111057132A
Methods of sequencing and producing nucleic acid sequences
CN112105748A
Tagged nucleoside compounds useful for nanopore detection
US20200385803A1
Mirror nucleic acid replication system
WO2017028548A1
Cited By
L-nucleic acid aptamer sensor for high-sensitivity detection of D-lactic acid
CN119757294A
